A transdiagnostic meta-analysis of acute augmentations to psychological therapy

Camilla L. Nord [1] ✉, Beth Longley[1,2], Quentin Dercon [1,3], Veronica Phillips [4], Julia Funk[5], Siobhan Gormley[1], Rachel Knight[1], Alicia J. Smith[1] & Tim Dalgleish [1,6]

At least half of all patients with mental health disorders do not respond adequately to psychological therapy. Acutely enhancing particular biological or psychological processes during psychological therapy may improve treatment outcomes. However, previous studies are confined to specific augmentation approaches, typically assessed within single diagnostic categories. Our objective was to assess to what degree acute augmentations of psychological therapy reduce psychiatric symptoms and estimate effect sizes of augmentation types (for example, brain stimulation or psychedelics). We searched Medline, PsycINFO and Embase for controlled studies published between database inception and 25 May 2022. We conducted a preregistered random-effects meta-analysis (PROSPERO CRD42021236403). We identified 108 studies ($N = 5,889$). Acute augmentation significantly reduced the severity of mental health problems (Hedges' $g = -0.27$, 95% CI: [-0.36, -0.18]; $P < 0.0001$), particularly for the transdiagnostic dimensions 'Fear' and 'Distress'. This result survived a trim-and-fill analysis to account for publication bias. Subgroup analyses revealed that pharmacological, psychological and somatic augmentations were effective, but to varying degrees. Acute augmentation approaches are a promising route to improve outcomes from psychological therapy.

Mental ill health is the leading cause of global disability[1], with an estimated economic cost of nearly £119 billion in the United Kingdom alone[2]. Although treatment efficacy and availability for psychiatric disorders have improved over the past 30 years, population prevalence remains high[3]. Psychological therapy (also known as psychotherapy or talk therapy) confers widespread improvements in the disability, mortality and occupational health of patients with mental health conditions, including severe mental illness, particularly when combined with pharmacological treatment[4–8]. Yet even the best therapies leave substantial proportions of patients with ongoing clinical problems[3].

To improve this, over the past two decades, acute augmentations of psychological therapy have gained traction in experimental

neuroscience and psychology. Acute augmentations are interventions delivered before, during or after a session of psychological therapy, with the intention of enhancing the therapeutic impact of a single session of therapy (although acute augmentations can and often are repeated across multiple therapy sessions). This approach is distinct from long-term combination therapy, which describes two independently efficacious therapies that may (or may not) convey additive benefits when used in the same patients (such as daily antidepressant medication prescribed alongside a course of psychological therapy). By contrast, the rationale for acute augmentation is to enhance specific biological or psychological mechanisms of an individual psychological therapy session. For example, a pharmacological agent or cognitive training

[1]MRC Cognition and Brain Sciences Unit, University of Cambridge, Cambridge, UK. [2]Division of Psychology and Mental Health, University of Manchester, Manchester, UK. [3]Department of Psychiatry, University of Oxford, Oxford, UK. [4]Medical Library, University of Cambridge, Cambridge, UK. [5]Department of Psychology, LMU Munich, Munich, Germany. [6]Cambridgeshire and Peterborough National Health Service Foundation Trust, Cambridge, UK. ✉e-mail: camilla.nord@mrc-cbu.cam.ac.uk

task might be administered to enhance the impact of a particular aspect of the therapy session, such as mental imagery[9] or fear extinction[10].

Acute augmentations often originate from basic experimental science. For instance, experimental neuroscience studies found the partial N-methyl-D-aspartate agonist D-cycloserine, administered before or shortly after exposure to a feared stimulus, enhanced fear extinction[10]. This discovery led to early-stage trials showing that D-cycloserine has a small but significant augmentative effect on the clinical efficacy of exposure-based cognitive behavior therapy for anxiety, obsessive–compulsive and posttraumatic stress disorders[11]. A similar translational process occurred in the psychological literature: influential models suggest that patients with affective disorders[12] have disrupted processing of negatively valenced information. These cognitive biases are proposed to play a causal role in development and maintenance of various psychiatric disorders[13]. This led to trials testing cognitive bias modification as an acute enhancement of psychological therapy for social anxiety[14], panic[15] and obsessive–compulsive disorder[16], among others. Separately, studies have examined the augmentative effects of somatic interventions such as non-invasive brain stimulation[17–23], exercise[24] and controlled breathing[25,26] on psychological therapy.

While augmentation studies focus almost exclusively on single-diagnosis populations, these examples illustrate that similar or identical augmentations are often tested across multiple patient populations on the basis of similar theoretical grounding. As such, augmentation approaches are likely to have transdiagnostic mechanisms and utility. This echoes a general increasing recognition that psychological treatments and their underlying mechanisms transcend diagnostic boundaries[27].

It is currently unknown whether augmentative interventions for psychological therapies are potentially useful across a range of disorders and augmentation approaches. To address this gap in the evidence, we conducted a meta-analysis across the extant literature to determine whether acute augmentation of manualized psychological therapy was generally effective for transdiagnostic psychiatric symptoms. Our goal was to quantify the effect sizes of augmentations of psychological therapies. We included a diverse range of acute augmentations, including medications, brain stimulation and cognitive training. This enabled us to assess the overall efficacy of acute augmentations of psychological therapy, as well as examine specific subcategories of augmentation.

Results

Results of initial and updated searches
The initial search results (conducted February 2021) included 12,458 unique studies; the updated search (May 2022) identified a further 1,984 studies (Fig. 1 and Supplementary Tables 1 and 2). Two independent raters screened the titles and abstracts of all studies, after which 12,193 studies were excluded (initial search) followed by 1,907 studies being excluded (updated search) when they did not meet one or more of our prespecified criteria. Raters were 97.29% concordant on the initial (2021) search, with a kappa value (indicating proportion of agreement to include/exclude beyond that expected by chance) of 0.43 (moderate agreement), and 96.27% concordant on the updated (2022) search, with a kappa value of 0.58 for the updated searches, indicating moderate-to-good agreement. Note the large number of abstracts screened (>12,000) likely contributes to the discrepancy between very high concordance (>95%) and moderate (although significantly better than chance) kappa (-0.5) (ref. 28). Following discussion to resolve discrepancies, both raters independently screened the full text of 265 studies (initial search) followed by 77 studies (updated search) to assess whether they met inclusion criteria.

The primary reason for excluding studies during full-text screening was the absence of an acute augmentative intervention (53 studies). After all screening, 108 studies were included in the meta-analysis, representing 5,889 participants.

Fig. 1 | Flow chart of screening protocol. PRISMA flow diagram describing the process of study identification, de-duplication, and screening (note this occurred at two time-points due to the updated search in May 2022).

Characteristics of included studies
The characteristics of each included study are listed in Supplementary Table 2. Of the 108 included studies, 59 involved pharmacological augmentations (2,381 patients), 26 had psychological or cognitive augmentations (2,442 patients) and 20 used somatic augmentations (951 patients). Three studies were included in the primary analysis but excluded from the subgroup analyses as they did not clearly represent any of the three subgroups. All studies were consistently categorized into one of these three groups (or excluded) by the two reviewers (100% concordance). Note that all augmentations tested in two or more studies included in the meta-analysis were 'transdiagnostic' (tested in at least two diagnostic/clinical categories) (Table 1).

Data synthesis
We found a significant advantage for augmentation groups over control groups with a small-to-moderate effect size (Hedges' g = −0.27, 95% confidence interval (CI): [−0.36, −0.18]; $P < 0.0001$) in the full sample (N = 5,889) (Fig. 2).

Next, we conducted planned subgroup analyses, additionally reporting Bonferroni correction for multiple comparisons, to determine whether certain types of augmentations were more efficacious than others. All three subgroups (pharmacological, psychological and somatic) showed efficacy at $P = 0.05$, but only pharmacological and somatic interventions showed efficacy at our Bonferroni-corrected alpha ($P = 0.016$). Effect sizes also varied between augmentation subgroups: the effect size for trials using pharmacological augmentations alone (59 studies; N = 2,381) was comparable to the overall effect size (Hedges' g = −0.28, 95% CI: [−0.42, −0.15]; $P < 0.0001$) (Fig. 3A). Studies using a psychological or cognitive augmentation (26 studies, N = 2,442) had a smaller effect-size estimate (Hedges' g = −0.18, 95% CI: [−0.33, −0.027]; $P = 0.0225$) (Fig. 3B). Studies using a somatic augmentation

**Table 1 | Augmentation types according to diagnostic/
clinical category in which they were tested**

Augmentation type	Clinical category
Memory	**MDD, phobia, PTSD**
Imagery	**PTSD, social anxiety**
Cortisol	**Phobia**
D-cycloserine	**OCD, PTSD, schizophrenia, social anxiety, SUD, panic disorder, phobia, body dysmorphic disorder**
Brain stimulation	**MDD, anxiety, phobia, SUD, PTSD**
Psychotropic	**PTSD, social anxiety, MDD, panic disorder, comorbid PTSD–SUD, anxiety, adjustment disorder**
Oxytocin	**Phobia, schizophrenia, PTSD, SUD**
Yohimbine	**Phobia, social anxiety, PTSD**
Motivational	**PTSD, OCD, anxiety, PTSD**
Bias modifications	**Panic disorder, OCD**
Exercise	Panic disorder, MDD
Breathing training	MDD, phobia
Animal-assisted	SUD, PTSD
Hypnosis	Acute stress, depression
Virtual reality	Binge-eating disorder, phobia
Hydrocortisone	Phobia, PTSD

All augmentations tested in at least two studies are listed (augmentations tested in three or more studies are indicated in bold to highlight their inclusion in the subgroup meta-analyses). MDD, major depressive disorder; OCD, obsessive–compulsive disorder; PTSD, posttraumatic stress disorder; SUD, substance-use disorder.

(20 studies; N = 951) had a larger effect-size estimate but a much wider confidence interval (Hedges' g = −0.39, 95% CI: [−0.66, −0.13]; P = 0.0063) (see Fig. 3C).

Exploratory analyses
We conducted two sets of exploratory analyses to examine in more detail the relative efficacy of specific augmentation subtypes and transdiagnostic dimensions.

To examine the relative efficacy of specific augmentation subtypes, we divided the dataset into ten categories, representing finer-grained augmentation approaches. Only those categories with a minimum of three studies per approach were analyzed (k = 66 studies met this criterion; see Supplementary Information for included studies). In these preliminary analyses, there was a striking variation between effect sizes of different subtypes. Augmentations using psychedelics, 3,4-methylenedioxy methamphetamine (MDMA, or ecstasy) and cannabis (k = 13, labeled 'psychotropic' in the following) had a large significant effect (Hedges' g = −0.84, 95% CI: [−1.26, −0.42]; P = 0.0009), which remained after exclusion of a wait-list-controlled study (Hedges' g = −0.69, 95% CI: [−1.04, −0.34]; P = 0.001). D-cycloserine (k = 24) also had a significant, but small, effect size (Hedges' g = −0.21, 95% CI: [−0.37, −0.037]; P = 0.019). Other subtypes had non-significant effects, which in some cases may due to low statistical power (for example, brain stimulation: (Hedges' g = −0.28, 95% CI: [−0.6, 0.03]; P = 0.072)) (Supplementary Table 6).

We also classified each study into clinical categories using the Hierarchical Taxonomy of Psychopathology, a transdiagnostic approach for classifying psychiatric disorders[29]. According to this approach, transdiagnostic augmentations were efficacious for Fear and Distress dimensions (Fear: Hedges' g = −0.26, 95% CI: [−0.40, −0.12]; P = 0.0004; Distress: Hedges' g = −0.28, 95% CI: [−0.44, −0.13]; P = 0.0008, with 'Fear' encompassing traditional categories of phobias, panic and social anxiety and 'Distress' encompassing dysphoria,

suicidality and generalized anxiety disorder, among others). Augmentation approaches were not effective for 'Substance abuse' or 'Thought disorder' dimensions, although these analyses were probably underpowered due to the substantially fewer studies represented (nine and three, respectively) (Substance abuse: Hedges' g = −0.40, 95% CI: [−0.87, 0.065]; P = 0.083; Thought disorder: Hedges' g = −0.11, 95% CI: [−0.41, 0.20]; P = 0.278) (Supplementary Information section 2.7).

Heterogeneity and publication bias
To measure between-study heterogeneity, we calculated the I^2 statistic[30]. The I^2 showed moderate heterogeneity (I^2 = 56.2%, 95% CI: [45.7%, 64.7%]; Cochran's Q = 244.4, P < 0.0001) across all study subcategories: pharmacological (I^2 = 50.0%, 95% CI: [33.7%, 63.6%]; Cochran's Q = 118.1, P < 0.0001), psychological (I^2 = 53.6%, 95% CI: [27.6%, 70.3%]; Cochran's Q = 53.9, P = 0.0007) and somatic (I^2 = 67.8%, 95% CI: [48.7%, 79.8%], Cochran's Q = 59.0, P < 0.0001).

We conducted an exploratory follow-up analysis repeating our main analysis but excluding outliers, defined as having confidence intervals not overlapping with the confidence intervals of the pooled effect. Sixteen outliers were found (nine pharmacological, three psychological and four somatic: Supplementary Table 3). After exclusion of outliers, there was no longer significant between-study heterogeneity: I^2 = 9.8% (95% CI: [0%; 31.1%]), Cochran's Q = 100.9, P = 0.2243. Nevertheless, evidence for our main effect remained (Hedges' g = −0.21, 95% CI: [−0.27; −0.14]; P < 0.0001).

Visual inspection of the funnel plot (Fig. 4a) showed some moderate asymmetry; 79.6% of studies fell within the funnel. Egger's regression test confirmed asymmetry (t(106) = −4.02, P = 0.0001), which was unchanged by excluding outliers (Egger's regression test t(90) = −4.00, P = 0.0001). A trim-and-fill analysis was then run, which added seven studies to the right-hand side of the funnel plot (Fig. 4b). Although this again slightly decreased the overall estimated effect size, evidence for our main effect remained strong (Hedges' g = −0.21, 95% CI: [−0.32; −0.11]; P = 0.0001).

Risk-of-bias analysis
We analyzed the risk of study bias using the Cochrane risk-of-bias tool. We assessed the presence of random sequence generation, concealment of allocation, blinding of participants and treatment providers, blinding of outcome assessment and incomplete outcome data, indicating whether each of these criteria was present, absent or uncertain (Supplementary Table 4). Note the presence of some degree of risk of bias across most studies.

To assess the contribution of risk of bias overall, we repeated our primary analysis excluding studies without certain blinded outcome assessment, which we determined to be the most critical risk of experimenter bias in acute augmentations of psychotherapy trials. We found 15 studies without, or with uncertain, blinding of outcome assessment.

Excluding these 'high-risk' studies and analyzing only 'lower-risk' studies did not alter our main effect, supporting the efficacy of brief augmentations (Hedges' g = −0.29, 95% CI: [−0.39, −0.19]; P < 0.0001) (Supplementary Fig. 3). Analyzing only high-risk studies, by contrast, did not support the efficacy of brief augmentations (Hedges' g = −0.19, 95% CI: [−0.45, 0.07]; P = 0.013) (Supplementary Fig. 4). This suggests this bias was not a major driver of our effect.

Sensitivity analyses
We conducted a number of sensitivity analyses to assess the robustness of our effect. First, we replicated our effect when excluding the small number (k = 2) of non-randomized trials (Hedges' g = −0.27, 95% CI: [−0.36, −0.17]; P < 0.0001) (Supplementary Fig. 7) (the two non-randomized studies themselves did not replicate the effect (Hedges' g = −0.64, 95% CI = [−4.62, −0.17]; P < 0.0001) and studies without an active therapeutic control (wait list; k = 2) (Hedges' g = −0.26, 95% CI: [−0.35, −0.17]; P < 0.0001).

Study	Augmentation N	Mean	s.d.	Control N	Mean	s.d.	SMD	95% CI	Weight (%)
Acheson et al. (2015)[138]	10	63.86	24.03	13	44.66	22.95	0.79	[−0.07, 1.65]	0.7
Alladin and Alibhai (2007)[51]	42	17.50	8.50	42	21.30	7.20	−0.48	[−0.91, −0.04]	1.3
Andersson et al. (2015)[49]	64	13.86	6.50	64	11.77	5.95	0.33	[−0.02, 0.68]	1.5
Arntz et al. (2007)[69]	28	18.52	14.50	39	17.63	13.76	0.06	[−0.42, 0.55]	1.2
Aust et al. (2022)[70]	43	14.40	6.90	42	15.70	7.30	−0.18	[−0.61, 0.24]	1.3
Baker et al. (2020)[15]	11	3.36	3.11	12	6.82	4.09	−0.91	[−1.78, −0.04]	0.7
Bischoff et al. (2018)[24]	39	12.00	7.60	38	13.00	7.50	−0.13	[−0.58, 0.32]	1.3
Bouso et al. (2008)[32]	3	28.30	10.48	2	40.00	1.41	−0.98	[−3.12, 1.15]	0.2
Brooks et al. (2021)[68]	10	−47.70	8.60	13	−49.80	10.70	0.21	[−0.62, 1.03]	0.7
Bryant et al. (2005)[139]	30	11.30	9.98	33	16.58	12.50	−0.46	[−0.96, 0.04]	1.2
Bryant et al. (2008)[140]	59	43.27	35.11	59	55.72	29.54	−0.38	[−0.75, −0.02]	1.4
Buchanan et al. (2021)[141]	22	125.30	20.30	20	126.30	17.40	−0.05	[−0.66, 0.55]	1.0
Burton et al. (2019)[142]	10	48.70	12.70	10	53.60	15.40	−0.33	[−1.22, 0.55]	0.6
Cesa et al. (2013)[143]	27	45.00	13.90	39	49.97	14.30	−0.35	[−0.84, 0.15]	1.2
Chien et al. (2015)[25]	43	11.58	4.51	46	12.74	4.19	−0.26	[−0.68, 0.15]	1.3
Cobb et al. (2021)[19]	23	7.83	11.52	19	12.74	17.75	−0.33	[−0.94, 0.28]	1.0
Coffey et al. (2016)[144]	40	20.49	17.87	86	21.54	19.57	−0.05	[−0.43, 0.32]	1.4
Contalbrigo et al. (2017)[145]	12	0.35	0.19	10	0.67	0.43	−0.96	[−1.85, −0.06]	0.6
Craske et al. (2019)[146]	39	0.20	0.56	21	0.58	0.50	−0.69	[−1.24, −0.15]	1.1
Danforth et al. (2018)[33]	8	46.40	15.20	4	64.00	13.30	−1.11	[−2.42, 0.21]	0.4
Davis et al. (2014)[71]	11	0.11	0.70	11	0.35	0.80	−0.31	[−1.15, 0.53]	0.7
Davis et al. (2017)[72]	26	33.54	8.41	47	32.59	12.61	0.08	[−0.40, 0.56]	1.2
Davis et al. (2021)[40]	13	8.50	5.70	11	23.50	6.00	−2.48	[−3.59, −1.37]	0.5
De Kleine et al. (2012)[85]	33	34.33	37.11	34	53.65	38.19	−0.51	[−0.99, −0.02]	1.2
de Leeuw et al. (2017)[86]	19	16.60	4.20	20	18.00	5.20	−0.29	[−0.92, 0.34]	1.0
De Quervain et al. (2011)[87]	20	30.40	13.86	20	40.20	13.86	−0.69	[−1.33, −0.05]	1.0
Difede et al. (2014)[88]	13	32.38	28.55	12	42.17	20.75	−0.38	[−1.17, 0.42]	0.7
Diminich et al. (2020)[89]	22	11.91	5.26	22	12.18	3.79	−0.06	[−0.65, 0.53]	1.0
Falkenstein et al. (2022)[16]	22	−0.33	0.75	8	0.96	1.05	−1.50	[−2.41, −0.60]	0.6
Fayaz et al. (2022)[90]	15	18.00	5.00	12	26.00	3.00	−1.83	[−2.75, −0.91]	0.6
Feng et al. (2019)[91]	60	34.30	12.60	60	46.00	13.20	−0.90	[−1.28, −0.52]	1.4
Flanagan et al. (2018)[92]	8	13.00	12.74	9	17.71	9.62	−0.40	[−1.36, 0.56]	0.6
Foa et al. (2005)[93]	74	16.80	13.20	79	17.90	14.50	−0.08	[−0.40, 0.24]	1.5
Fryml et al. (2019)[21]	5	36.00	36.71	3	43.30	35.23	−0.18	[−1.61, 1.26]	0.3
Guastella et al. (2008)[94]	28	89.52	22.63	28	99.30	27.26	−0.38	[−0.91, 0.14]	1.1
Guastella et al. (2009)[95]	12	96.57	20.19	13	91.41	30.59	0.19	[−0.60, 0.98]	0.7
Harb et al. (2019)[53]	40	3.20	1.56	38	2.70	1.52	0.32	[−0.13, 0.77]	1.3
Harvey et al. (2016)[52]	22	19.41	11.69	20	25.45	10.83	−0.52	[−1.14, 0.09]	1.0
Hofmann et al. (2006)[96]	10	81.74	27.01	13	96.21	37.74	−0.42	[−1.25, 0.42]	0.7
Hofmann et al. (2013)[97]	87	2.68	1.41	82	2.95	1.43	−0.19	[−0.49, 0.11]	1.6
Hofmeijer-Sevink et al. (2017)[98]	38	2.15	2.32	19	1.88	2.48	0.11	[−0.44, 0.66]	1.1
Hutschemaekers et al. (2021)[99]	27	38.22	21.22	27	36.88	20.84	0.06	[−0.47, 0.60]	1.1
Isserles et al. (2021)[100]	40	27.37	12.59	51	22.30	12.71	0.40	[−0.02, 0.82]	1.3
Isserles et al. (2013)[22]	9	61.00	26.40	9	76.00	32.10	−0.49	[−1.43, 0.45]	0.6
Janse et al. (2020)[101]	190	0.41	0.40	178	0.41	0.39	0.01	[−0.19, 0.22]	1.7
Kamboj et al. (2012)[102]	16	63.11	25.83	16	56.38	28.29	0.24	[−0.45, 0.94]	0.9
Kozel et al. (2018)[23]	31	31.11	22.49	30	38.29	24.43	−0.30	[−0.81, 0.22]	1.2
Krupitsky et al. (2002)[103]	35	3.97	5.04	35	15.06	16.54	−0.90	[−1.39, −0.40]	1.2
Kushner et al. (2007)[104]	14	10.90	4.70	11	11.20	6.80	−0.05	[−0.84, 0.74]	0.7
Kwee et al. (2022)[105]	39	35.38	18.24	39	37.13	17.26	−0.10	[−0.54, 0.35]	1.3
Lancaster et al. (2020)[106]	97	6.95	1.71	33	6.85	1.84	0.06	[−0.34, 0.45]	1.4
Lass-Hennemann and Michael (2014)[50]	30	4.60	0.34	30	5.27	0.47	−1.61	[−2.20, −1.02]	1.0
Lazarov et al. (2018)[14]	25	48.37	24.25	25	60.05	20.70	−0.51	[−1.07, 0.05]	1.1
Lee et al. (2020)[107]	22	−9.86	6.13	20	−7.94	3.37	−0.38	[−0.99, 0.24]	1.0
Lehrner et al. (2021)[108]	24	52.89	16.31	26	48.94	17.49	0.23	[−0.33, 0.79]	1.1
Leuchter et al. (2022)[109]	8	71.13	21.85	9	80.22	21.31	−0.40	[−1.36, 0.56]	0.6
Litz et al. (2012)[110]	13	72.33	28.63	13	53.73	26.22	0.66	[−0.14, 1.45]	0.7
Maples-Keller et al. (2017)[111]	45	65.55	49.88	44	76.57	47.46	−0.22	[−0.64, 0.19]	1.3
Marker et al. (2020)[112]	18	2.43	1.28	18	2.85	1.28	−0.32	[−0.98, 0.34]	0.9
McEvoy et al. (2020)[137]	51	36.91	2.17	54	36.24	1.82	0.33	[−0.05, 0.72]	1.4
Meyer et al. (2010)[113]	48	8.15	5.43	45	13.90	9.39	−0.75	[−1.17, −0.33]	1.3
Meyer et al. (2022)[114]	5	2.21	3.35	5	5.62	3.47	−0.90	[−2.24, 0.43]	0.3
Meyerbroeker et al. (2012)[115]	20	26.87	19.64	25	23.96	17.10	0.16	[−0.43, 0.75]	1.0
Meyerbröker et al. (2018)[116]	37	36.71	15.41	17	29.18	16.45	0.47	[−0.11, 1.05]	1.0
Mithoefer et al. (2011)[34]	12	29.30	22.52	8	66.80	22.63	−1.59	[−2.64, −0.54]	0.5
Mithoefer et al. (2018)[35]	19	37.49	30.12	7	76.00	23.40	−1.30	[−2.25, −0.36]	0.6
Morissette et al. (2008)[73]	4	5.15	1.05	4	4.40	1.33	0.54	[−0.89, 1.98]	0.3
Moshier and Otto (2017)[74]	21	23.10	10.80	13	18.60	13.30	0.37	[−0.33, 1.07]	0.9
Nations et al. (2012)[75]	24	6.64	3.78	13	6.60	4.29	0.01	[−0.67, 0.68]	0.9
Nejati et al. (2017)[20]	4	12.25	5.62	7	22.99	7.66	−1.39	[−2.81, 0.03]	0.3
Nicholas et al. (2022)[36]	42	3.24	3.36	40	3.23	3.65	0.00	[−0.43, 0.44]	1.3
Nord et al. (2019)[18]	20	12.65	6.91	19	14.37	5.81	−0.26	[−0.89, 0.37]	1.0
Oehen et al. (2013)[37]	8	50.80	19.70	4	66.50	7.60	−0.85	[−2.12, 0.42]	0.4
Ot'alora G et al. (2018)[38]	22	66.74	30.78	6	73.30	24.50	−0.21	[−1.12, 0.69]	0.6
Otto et al. (2010)[76]	13	3.58	1.96	14	6.77	3.30	−1.13	[−1.95, −0.31]	0.7
Pace-Schott et al. (2018)[77]	17	62.82	23.68	14	55.29	19.27	0.34	[−0.38, 1.05]	0.8
Powers et al. (2009)[78]	12	15.42	13.39	12	27.08	21.37	−0.63	[−1.45, 0.19]	0.7
Pyrkosch et al. (2018)[79]	36	21.16	8.81	33	19.79	9.89	0.15	[−0.33, 0.62]	1.2
Raeder et al. (2019)[80]	20	26.05	14.35	23	32.17	19.72	−0.34	[−0.95, 0.26]	1.0
Reinecke et al. (2020)[81]	17	2.10	17.20	14	21.30	30.80	−0.77	[−1.51, −0.03]	0.8
Reitmaier et al. (2022)[82]	27	64.45	19.13	26	56.46	24.76	0.36	[−0.19, 0.90]	1.1
Rodebaugh et al. (2013)[83]	18	55.89	20.46	16	65.85	20.19	−0.48	[−1.16, 0.21]	0.9
Ross et al. (2016)[41]	12	7.45	4.81	14	13.88	5.19	−1.24	[−2.09, −0.39]	0.7
Ross et al. (2021)[117]	6	40.33	10.97	5	49.01	17.87	−0.55	[−1.77, 0.67]	0.4
Rubin et al. (2022)[118]	10	123.50	21.21	8	119.63	19.54	0.18	[−0.75, 1.11]	0.6
Santa Ana et al. (2015)[119]	23	0.76	1.37	24	1.42	1.89	−0.39	[−0.97, 0.19]	1.0
Sherman et al. (2017)[120]	8	1.05	1.65	7	0.79	1.39	0.16	[−0.86, 1.18]	0.5
Shiban et al. (2017)[26]	15	1.06	0.63	14	1.29	0.84	−0.30	[−1.04, 0.43]	0.8
Siegmund et al. (2011)[121]	20	11.85	6.05	19	17.26	2.28	−1.15	[−1.83, −0.46]	0.9
Simpson et al. (2010)[122]	15	11.90	2.35	15	13.75	3.60	−0.59	[−1.33, 0.14]	0.8
Sippel et al. (2020)[123]	6	20.50	19.53	7	29.71	26.39	−0.36	[−1.47, 0.74]	0.5
Smits et al. (2006)[124]	35	58.48	24.33	33	58.97	23.01	−0.02	[−0.50, 0.46]	1.2
Smits et al. (2014)[125]	20	38.78	10.24	20	47.19	10.49	−0.80	[−1.44, −0.15]	0.9
Smits et al. (2020)[126]	114	60.56	23.34	38	65.88	25.16	−0.22	[−0.59, 0.15]	1.4
Smits et al. (2020)[127]	27	15.37	10.38	26	17.80	13.77	−0.20	[−0.74, 0.34]	1.1
Soravia et al. (2014)[128]	11	43.30	11.28	11	53.50	17.58	−0.66	[−1.53, 0.20]	0.7
Soucy et al. (2021)[129]	203	6.26	4.78	231	6.22	5.05	0.01	[−0.18, 0.20]	1.8
Steudte-Schmiedgen et al. (2021)[130]	17	14.17	2.39	16	15.95	3.92	−0.54	[−1.24, 0.16]	0.9
Storch et al. (2007)[131]	12	10.10	6.80	12	8.60	8.80	0.18	[−0.62, 0.99]	0.7
Tart et al. (2013)[132]	15	29.73	25.67	14	35.55	25.18	−0.22	[−0.95, 0.51]	0.8
Thierree et al. (2022)[147]	13	41.80	31.90	16	51.60	23.70	−0.34	[−1.08, 0.39]	0.8
Tuerk et al. (2018)[133]	14	71.01	14.37	12	75.08	10.77	−0.31	[−1.08, 0.47]	0.8
Vermes et al. (2020)[134]	21	0.36	0.60	21	0.51	0.44	−0.28	[−0.89, 0.33]	1.0
Weingarden et al. (2019)[135]	12	19.64	6.80	14	18.77	10.03	0.10	[−0.67, 0.87]	0.8
Wilhelm et al. (2008)[136]	10	10.20	7.20	13	14.50	6.40	−0.61	[−1.46, 0.23]	0.7
Witkiewitz et al. (2019)[17]	47	5.12	3.14	37	5.64	4.06	−0.14	[−0.58, 0.29]	1.3
Wolfson et al. (2020)[39]	13	38.90	10.60	5	48.60	12.60	−0.83	[−1.91, 0.25]	0.5
Zoellner et al. (2017)[84]	15	17.10	10.57	16	14.67	9.27	0.24	[−0.47, 0.95]	0.8
Random-effects model	3,035			2,854			−0.27	[−0.36, −0.18]	100.0
Prediction interval								[−0.91, 0.36]	

Heterogeneity: $I^2 = 56\%$, $\tau^2 = 0.1010$, $P < 0.01$

−3 −2 −1 0 1 2 3
Augmentation   Control

Fig. 2 | Synthesis of all studies included in the random-effects meta-analysis. The primary outcome of our random-effects meta-analysis of the included acute augmentation studies, i.e. the difference between the two groups at post-treatment (standardised mean difference: SMD) and the 95% confidence interval (CI) around the effect size. Data from refs. 14–26,32–39,41,49–53,68–147.

a

Study	N	Augmentation Mean	s.d.	N	Control Mean	s.d.	SMD	95% CI	Weight (%)
Acheson et al. (2015)[138]	10	63.86	24.03	13	44.66	22.95	0.79	[-0.07; 1.65]	1.4%
Andersson et al. (2015)[49]	64	13.86	6.50	64	11.77	5.95	0.33	[-0.02; 0.68]	2.9%
Bouso et al. (2008)[32]	3	28.30	10.48	2	40.00	1.41	-0.98	[-3.12; 1.15]	0.3%
Buchanan et al. (2021)[141]	22	125.30	20.30	20	126.30	17.40	-0.05	[-0.66; 0.55]	2.0%
Craske et al. (2019)[146]	39	0.20	0.56	21	0.58	0.50	-0.69	[-1.24; -0.15]	2.2%
Danforth et al. (2018)[33]	8	46.40	15.20	4	64.00	13.30	-1.11	[-2.42; 0.17]	0.7%
Davis et al. (2014)[71]	11	0.11	0.70	11	0.35	0.80	-0.31	[-1.15; 0.53]	1.4%
Davis et al. (2021)[40]	13	8.50	5.70	11	23.50	6.00	-2.48	[-3.59; -1.37]	1.0%
De Kleine et al. (2012)[85]	33	34.33	37.11	34	53.65	38.19	-0.51	[-0.99; -0.02]	2.4%
de Leeuw et al. (2017)[86]	19	16.60	4.20	20	18.00	5.20	-0.29	[-0.92; 0.34]	1.9%
De Quervain et al. (2011)[87]	20	30.40	13.86	20	40.20	13.86	-0.69	[-1.33; -0.05]	1.9%
Difede et al. (2014)[88]	13	32.38	28.51	12	42.17	20.75	-0.38	[-1.17; 0.42]	1.5%
Diminich et al. (2020)[89]	22	11.91	5.26	22	12.18	3.79	-0.06	[-0.65; 0.53]	2.0%
Flanagan et al. (2018)[92]	8	13.00	12.74	9	17.71	9.62	-0.40	[-1.36; 0.56]	1.2%
Guastella et al. (2008)[94]	28	89.52	22.63	28	99.30	27.26	-0.38	[-0.91; 0.14]	2.2%
Guastella et al. (2009)[95]	12	96.57	20.19	14	91.41	30.59	0.19	[-0.60; 0.98]	1.5%
Hofmann et al. (2006)[96]	10	81.74	27.01	13	96.21	37.74	-0.42	[-1.25; 0.42]	1.4%
Hofmann et al. (2013)[97]	87	2.68	1.41	82	2.95	1.43	-0.19	[-0.49; 0.11]	3.1%
Hofmeijer-Sevink et al. (2017)[98]	38	2.15	2.32	19	1.88	2.48	0.11	[-0.44; 0.66]	2.2%
Hutschemaekers et al. (2021)[99]	27	38.22	21.22	27	36.88	20.84	0.06	[-0.47; 0.60]	2.2%
Kamboj et al. (2012)[102]	16	63.11	25.83	16	56.38	28.29	0.24	[-0.45; 0.94]	1.7%
Krupitsky et al. (2002)[103]	35	3.97	5.04	35	15.06	16.54	-0.90	[-1.39; -0.40]	2.4%
Kushner et al. (2007)[104]	14	10.90	4.70	11	11.20	6.80	-0.05	[-0.84; 0.74]	1.5%
Kwee et al. (2022)[105]	39	35.38	18.24	39	37.13	17.26	-0.10	[-0.54; 0.35]	2.5%
Lehrner et al. (2021)[108]	24	52.89	16.31	26	48.94	17.49	0.23	[-0.33; 0.79]	2.2%
Litz et al. (2012)[110]	12	72.33	28.63	13	53.73	26.22	0.66	[-0.14; 1.45]	1.5%
Meyerbroeker et al. (2012)[115]	20	26.87	19.64	25	23.96	17.10	0.16	[-0.43; 0.75]	2.1%
Meyerbroker et al. (2018)[116]	37	36.71	15.41	17	29.18	16.45	0.47	[-0.11; 1.05]	2.1%
Mithoefer et al. (2011)[34]	12	29.30	22.52	8	66.80	22.63	-1.59	[-2.64; -0.54]	1.0%
Mithoefer et al. (2018)[35]	19	37.49	30.12	7	76.00	23.40	-1.30	[-2.25; -0.36]	1.2%
Morissette et al. (2008)[73]	4	5.15	1.05	4	4.40	1.33	0.54	[-0.89; 1.98]	0.6%
Nations et al. (2012)[75]	24	6.64	3.78	13	6.60	4.29	0.01	[-0.67; 0.68]	1.8%
Nicholas et al. (2022)[36]	42	3.24	3.36	40	3.23	3.65	0.00	[-0.43; 0.44]	2.6%
Oehen et al. (2013)[37]	8	50.80	19.70	4	66.50	7.60	-0.85	[-2.12; 0.42]	0.8%
Ot'alora G et al. (2018)[38]	22	66.74	30.78	6	73.30	24.50	-0.21	[-1.12; 0.69]	1.3%
Otto et al. (2010)[76]	13	3.58	1.96	14	6.77	3.30	-1.13	[-1.95; -0.31]	1.4%
Powers et al. (2009)[78]	12	15.42	13.39	12	27.08	21.37	-0.63	[-1.45; 0.19]	1.4%
Pyrkosch et al. (2018)[79]	36	21.16	8.81	33	19.79	9.89	0.15	[-0.33; 0.62]	2.4%
Raeder et al. (2019)[81]	20	26.05	14.35	23	32.17	19.72	-0.34	[-0.95; 0.26]	2.0%
Reinecke et al. (2020)[80]	17	2.10	17.20	14	21.30	30.80	-0.77	[-1.51; -0.03]	1.6%
Rodebaugh et al. (2013)[83]	18	55.89	20.46	16	65.85	20.19	-0.48	[-1.16; 0.21]	1.8%
Ross et al. (2016)[41]	12	7.45	4.81	14	13.88	5.19	-1.24	[-2.09; -0.39]	1.4%
Ross et al. (2021)[117]	6	40.33	10.97	5	49.01	17.87	-0.55	[-1.77; 0.67]	0.8%
Santa Ana et al. (2015)[119]	23	0.76	1.37	24	1.42	1.89	-0.39	[-0.97; 0.19]	2.1%
Sherman et al. (2017)[120]	8	1.05	1.65	7	0.79	1.39	0.16	[-0.86; 1.18]	1.1%
Siegmund et al. (2011)[121]	20	11.85	6.05	19	17.26	2.28	-1.15	[-1.83; -0.48]	1.8%
Sippel et al. (2021)[123]	8	20.50	19.53	7	29.71	26.39	-0.36	[-1.41; 0.74]	1.0%
Smits et al. (2014)[125]	20	38.78	10.24	20	47.19	10.49	-0.80	[-1.44; -0.15]	1.9%
Smits et al. (2020)[126]	114	60.56	23.34	38	65.88	25.16	-0.22	[-0.59; 0.15]	2.8%
Smits et al. (2020)[127]	27	15.37	10.38	26	17.80	13.77	-0.20	[-0.74; 0.34]	2.2%
Soravia et al. (2021)[128]	11	43.30	11.28	11	53.50	17.58	-0.66	[-1.53; 0.20]	1.4%
Steudte-Schmiedgen et al. (2021)[130]	17	14.17	2.39	16	15.95	3.92	-0.54	[-1.24; 0.16]	1.7%
Storch et al. (2007)[131]	17	10.10	6.80	12	8.60	8.80	0.18	[-0.62; 0.99]	1.5%
Tart et al. (2013)[132]	15	29.73	25.67	14	35.55	25.18	-0.22	[-0.95; 0.51]	1.7%
Tuerk et al. (2018)[133]	14	71.01	14.37	12	75.08	10.77	-0.31	[-1.08; 0.47]	1.6%
Weingarden et al. (2019)[135]	12	19.64	6.80	14	18.77	10.03	0.10	[-0.67; 0.87]	1.6%
Wilhelm et al. (2008)[136]	10	10.20	7.20	13	14.50	6.40	-0.61	[-1.46; 0.23]	1.4%
Wolfson et al. (2020)[39]	13	38.90	10.60	5	48.60	12.60	-0.83	[-1.91; 0.25]	1.0%
Zoellner et al. (2017)[84]	15	17.10	10.57	16	14.67	9.27	0.24	[-0.47; 0.95]	1.7%
Random-effects model	1,287			1,094			-0.28	[-0.42; -0.15]	100.0%
Prediction interval								[-0.97; 0.40]	

Heterogeneity: $I^2 = 51\%$, $\tau^2 = 0.1118$, $P < 0.01$

Augmentation — Control

b

Study	N	Augmentation Mean	s.d.	N	Control Mean	s.d.	SMD	95% CI	Weight (%)
Alladin and Alibhai, 2007[51]	42	17.50	8.50	42	21.30	7.20	-0.48	[-0.91; -0.04]	4.3%
Arntz et al. (2007)[69]	28	18.52	14.50	39	17.63	13.76	0.06	[-0.42; 0.55]	3.9%
Baker et al. (2020)[15]	11	3.36	3.11	12	6.82	4.09	-0.91	[-1.78; -0.04]	1.8%
Bryant et al. (2005)[139]	30	11.30	9.98	33	16.58	12.50	-0.46	[-0.96; 0.04]	3.7%
Bryant et al. (2008)[140]	59	43.27	35.11	59	55.72	29.54	-0.38	[-0.75; -0.02]	5.1%
Cesa et al. (2013)[143]	27	45.00	13.90	39	49.97	14.30	-0.35	[-0.84; 0.15]	3.8%
Coffey et al. (2016)[144]	40	20.49	17.87	86	21.54	19.57	-0.05	[-0.43; 0.32]	4.9%
Falkenstein et al. (2022)[8]	22	-0.33	0.75	8	0.96	1.05	-1.50	[-2.41; -0.60]	1.7%
Foa et al. (2005)[93]	74	16.80	13.20	79	17.90	14.50	-0.08	[-0.40; 0.24]	5.6%
Harb et al. (2019)[53]	40	3.20	1.56	38	2.70	1.52	0.32	[-0.13; 0.77]	4.2%
Harvey et al. (2016)[52]	22	19.41	11.69	20	25.45	10.83	-0.52	[-1.14; 0.09]	2.9%
Janse et al. (2020)[101]	190	0.41	0.40	178	0.41	0.39	0.01	[-0.19; 0.22]	6.9%
Lancaster et al. (2020)[106]	97	6.95	1.71	33	6.85	1.84	0.06	[-0.34; 0.45]	4.7%
Lazarov et al. (2018)[14]	25	48.37	24.25	25	60.05	20.70	-0.51	[-1.07; 0.05]	3.3%
Lee et al. (2007)[107]	22	-9.86	6.13	20	-7.94	3.37	-0.38	[-0.99; 0.24]	3.0%
Maples-Keller et al. (2017)[111]	45	65.55	49.88	44	76.57	47.46	-0.22	[-0.64; 0.19]	4.5%
Marker et al. (2020)[112]	18	2.43	1.28	18	2.85	1.28	-0.32	[-0.98; 0.34]	2.7%
McEvoy et al. (2020)[137]	51	36.91	2.17	54	36.24	1.82	0.33	[-0.05; 0.72]	4.8%
Meyer et al. (2010)[113]	48	8.15	5.43	45	13.90	9.39	-0.75	[-1.17; -0.33]	4.5%
Moshier and Otto, 2017[74]	21	23.10	10.80	13	18.60	13.30	0.37	[-0.33; 1.07]	2.5%
Reitmaier et al. (2022)[82]	27	64.45	19.13	26	56.46	24.76	0.36	[-0.19; 0.90]	3.4%
Rubin et al. (2022)[18]	10	123.50	21.21	8	119.63	19.54	0.18	[-0.75; 1.11]	1.6%
Simpson et al. (2010)[122]	15	11.90	2.35	15	13.75	3.60	-0.59	[-1.33; 0.14]	2.3%
Smits et al. (2006)[124]	35	58.48	24.33	38	58.97	23.01	-0.02	[-0.50; 0.46]	4.0%
Soucy et al. (2021)[129]	203	6.26	4.78	231	6.22	5.05	0.01	[-0.18; 0.20]	7.1%
Vermes et al. (2020)[134]	21	0.36	0.60	21	0.51	0.44	-0.28	[-0.89; 0.33]	3.0%
Random-effects model	1,223			1,219			-0.18	[-0.33; -0.03]	100.0%
Prediction interval								[-0.67; 0.32]	

Heterogeneity: $I^2 = 54\%$, $\tau^2 = 0.0537$, $P < 0.01$

Augmentation — Control

c

Study	N	Augmentation Mean	s.d.	N	Control Mean	s.d.	SMD	95% CI	Weight (%)
Aust et al. (2022)[70]	43	14.40	6.90	42	15.70	7.30	-0.18	[-0.61; 0.24]	6.7%
Bischoff et al. (2018)[24]	39	12.00	7.60	38	13.00	7.50	-0.13	[-0.58; 0.32]	6.5%
Brooks et al. (2021)[68]	10	-47.70	8.60	13	-49.80	10.70	0.21	[-0.62; 1.03]	4.3%
Chien et al. (2015)[75]	43	11.58	4.51	46	12.74	4.19	-0.26	[-0.68; 0.15]	6.7%
Cobb et al. (2021)[19]	23	7.83	11.52	19	12.74	17.75	-0.33	[-0.94; 0.28]	5.5%
Fayaz et al. (2022)[90]	15	18.00	5.00	12	26.00	3.00	-1.83	[-2.75; -0.91]	3.9%
Feng et al. (2019)[91]	60	34.30	12.60	60	46.00	13.20	-0.90	[-1.28; -0.52]	7.0%
Frym et al. (2019)[21]	5	36.00	36.71	3	43.30	35.23	-0.18	[-1.61; 1.26]	2.2%
Isserles et al. (2021)[100]	40	27.37	12.59	51	22.30	12.71	0.40	[-0.02; 0.82]	6.7%
Isserles et al. (2013)[22]	9	61.00	26.40	9	76.00	32.10	-0.49	[-1.43; 0.45]	3.8%
Kozel et al. (2018)[23]	31	31.11	22.49	30	38.29	24.43	-0.30	[-0.81; 0.20]	6.2%
Lass-Hennemann and Michael (2014)[15]	30	4.60	0.34	30	5.27	0.47	-1.61	[-2.20; -1.02]	5.7%
Leuchter et al. (2022)[109]	9	71.13	21.85	9	80.22	21.31	-0.40	[-1.36; 0.56]	3.7%
Meyer et al. (2022)[114]	5	2.21	3.35	5	5.62	3.47	-0.90	[-2.24; 0.43]	2.4%
Nejati et al. (2017)[20]	4	12.25	5.62	7	22.99	7.66	-1.39	[-2.81; 0.03]	2.1%
Nord et al. (2017)[26]	20	12.65	6.91	19	14.37	5.81	-0.26	[-0.89; 0.37]	5.4%
Pace-Schott et al. (2018)[77]	17	62.82	23.68	14	55.29	19.27	0.34	[-0.38; 1.05]	4.9%
Shiban et al. (2017)[26]	15	1.06	0.63	14	1.29	0.84	-0.30	[-1.04; 0.43]	4.8%
Thierree et al. (2021)[147]	13	41.80	31.90	16	51.60	23.70	-0.34	[-1.08; 0.39]	4.8%
Witkiewitz et al. (2019)[17]	47	5.12	3.14	37	5.64	4.06	-0.14	[-0.58; 0.29]	6.6%
Random-effects model	477			474			-0.39	[-0.66; -0.13]	100.0%
Prediction interval								[-1.35; 0.57]	

Heterogeneity: $I^2 = 68\%$, $\tau^2 = 0.1923$, $P < 0.01$

Augmentation — Control

Fig. 3 | Forest plots of study subcategories in the random-effects meta-analysis. a, Pharmacological. **b**, Psychological. **c**, Somatic. Data from refs. 14–26,32–39,41, 49–53,68–147.

We performed a further sensitivity analysis, excluding six studies where (although meeting our own inclusion criteria) the study authors framed the study as more combinatory than augmentative in nature. This did not alter our main analysis results (Hedges' $g = -0.28$, 95% CI: [−0.37, −0.18]; $P < 0.0001$) (Supplementary Fig. 6). However, the remaining 20 psychological augmentation studies showed a reduced and now non-significant effect of augmentation: Hedges' $g = -0.16$, 95% CI: [− 0.35, 0.03]; $P = 0.089$ (Supplementary Fig. 5).

Discussion

We conducted a transdiagnostic meta-analysis to estimate the effect size of acutely augmented psychological therapy, compared with a control or non-augmented therapy. On our preregistered primary outcome, we found that acute augmentations of psychological therapy are efficacious for a diverse array of mental health problems, with an overall small effect size. Examining specific transdiagnostic dimensions and intervention types, we found support for the use of acute augmentations for fear- and distress-based mental health problems and for interventions employing acute pharmacological (for example, the psychedelic compound psilocybin) and somatic (for example, transcranial magnetic stimulation) augmentations of psychological therapy. This suggests that augmenting specific therapy sessions with medication or brain stimulation interventions (among others) could improve clinical response to psychological therapy.

Although we found evidence for overall moderate efficacy of acute augmentations, we also reported substantial heterogeneity among all types of studies. This did not seem to be driving our overall effect:

excluding a small number of outliers ($k = 15$), heterogeneity decreased substantially while the effect of acute augmentations remained with a near-equal magnitude. Similarly, a number of sensitivity analyses did not substantially alter our finding, suggesting that our overall effect was not driven by poor outcome blinding and lack of randomization, which affected a small number of studies.

The small effect size we report is comparable to the effect size recently found in a large umbrella review for the combination of psychotherapy and pharmacotherapy, compared with either as a monotherapy[31]. This is compelling because the nature of long-term (compared with brief) augmentation is very different, commonly associated with different disorders (major depression versus phobias), and far fewer administrations of a medication take place in the context of brief pharmacological augmentations than during longer-term combination therapies. Potentially, the lower intensity and chronicity of brief interventions may offer a similar benefit with fewer adverse effects and at reduced cost; this is an important topic for investigation in future work.

An additional implication of our results is that certain brief augmentations may confer much larger effects than either other brief augmentations or, indeed, long-term combination of psychotherapy and pharmacotherapy. Our meta-analysis included three broad types of augmentation trials: psychological, pharmacological and somatic. In exploratory analyses, we found that all three acute augmentations were somewhat efficacious, but to varying degrees. We found particularly robust evidence for pharmacological augmentations, which also comprised the largest group of acute augmentations. This is exemplified

Fig. 4 | Funnel plot of all studies. a, To evaluate publication bias, we plotted the standardized mean difference of each study with respect to its standard error. We visually inspected the plot for asymmetry: 79.6% of studies fell within the funnel. **b**, We then ran a trim-and-fill analysis, which added seven studies.

in the case of *d*-cycloserine augmentations of psychological therapy, which represented the largest single augmentation type in our meta-analysis and had a similarly small effect size to our overall effect. Previous meta-analyses have reported a small advantage of d-cyclo-serine-enhanced exposure therapy, albeit with notable between-study variation[11], a conclusion supported by our meta-analysis.

Our meta-analysis also included a number of more atypical acute pharmacological augmentations, such as eight studies testing MDMA (ecstasy)[32–39] or psilocybin[40,41] as therapeutic augmentations, an area of substantial current interest in the psychiatric research community[42–44]. We found evidence for a large significant effect of recreational drugs as therapeutic enhancers ($d = -0.84$, comprising MDMA, psilocybin and cannabis augmentations) in a subanalysis of 13 such studies ($N = 412$). This compares favorably with the significant but smaller effects of *d*-cycloserine ($d = 0.21$). Our meta-analysis suggests that psychedelic and related compounds may be particularly effective brief therapeutic enhancers.

By contrast, we found weaker evidence for various psychological augmentations ($d = -0.18$), the efficacy of which was not as robust as the other groups of interventions; this did not survive analyses of specific augmentation types (memory, imagery, motivation or bias training) or exclusion of studies framed as more 'combinatory' than augmentative. While somatic augmentations had the largest effect size of the three, the estimate of this effect was less precise (95% CI: [−0.66, −0.13]. This is probably a reflection of this category's relatively smaller size and/or greater heterogeneity among the augmentations, which included brain stimulation, sleep, time of day, exercise and controlled breathing. We had sufficient studies to perform an exploratory subanalysis on the somatic subcategory of brain stimulation, which showed a significant effect (smaller than psychedelic and related drugs but of a similar magnitude to the overall effect of augmentations ($d = 0.28$)). In future, precise estimates of other somatic augmentations' efficacy could be obtained by splitting this category into its constituent parts (requiring more studies with particular somatic augmentation approaches).

Recent efforts have been made to characterize the 'active ingredients' of mental health treatment: that is, the aspects of an intervention that drive clinical effects[45]. This approach may hold particular potential for uncovering acute augmentation strategies. By first identifying key therapeutic mechanisms of action via reverse translation, acute therapeutic augmentations can be applied in novel combinations to specifically target those mechanisms. For instance, mental imagery is thought be an 'active ingredient' of effective psychological therapy[46]. Techniques designed to enhance mental imagery have been widely studied as acute augmentations of psychological therapies, with some evidence of success, particularly in young people[46]. Outside of a

research setting, imagery-enhanced group cognitive behavior therapy is a highly effective intervention, even when delivered by trainee clinicians in independent settings[9]. Future work could establish whether imagery-based psychological augmentation could be particularly helpful in certain patients or at certain points in a longer course of therapy. Unlike chronic, long-term combination therapies, acute augmentations support modular therapy: during a course of therapy, d-cycloserine might be used in one session dedicated to exposure; brain stimulation might be used at a later session focusing on cognitive restructuring.

Acute augmentations of psychological therapy hold particular promise as tests of whether particular approaches can be subject to clinical translation. For example, as with previous psychological augmentation approaches such as imagery, acute pharmacological augmentations could also focus on targeting specific active ingredients of psychological therapy. This strategy could be helpful for individuals unlikely to respond to psychological therapy alone. For example, patients with pathological disgust respond generally poorly to exposure therapy; our recent experimental work suggests that a peripherally selective dopamine antagonist may enhance disgust habituation, an active ingredient of exposure therapy[47]. Alternatively or in addition, specific neural effects of psychological therapy might be used as future targets of augmentation, for example, with brain stimulation interventions.

A limitation of our meta-analysis is its potential for bias due to existing issues with scientific robustness in the clinical literature. This was seen both in the risk-of-bias assessment, where most studies showed some degree of bias, and in the funnel plot of the effect-size estimates of individual studies against their standard errors, where we found some evidence of asymmetry in our sample of studies. In the absence of publication bias (or any other sources of heterogeneity biased by sample size), 95% of studies should fall inside the funnel of the plot[48]; in our results, approximately 80% of studies fall within the funnel. This probably indicates some publication bias in the augmentation literature, potentially due to selective outcome reporting or under-reporting of null results. This could have inflated our estimates of effect size. However, asymmetry in funnel plots can also be caused by sources of heterogeneity that are genuinely associated with sample size, such as smaller studies having higher treatment fidelity or larger studies generally delivering less-intense interventions due to feasibility[48], which are plausible in the context of the acute augmentation literature. In our sample, both publication bias and true sources of heterogeneity may have contributed to our findings. Crucially, our central results survived correction for publication bias with trim and fill.

A second caveat originates from the transdiagnostic approach employed in this meta-analysis. A risk of this approach is that it obscures

the effectiveness or ineffectiveness of augmentations for particular subcategories of symptoms, such as eating-disorder symptoms, which were under-represented in our studies. In partial mitigation of this concern, trials measuring these symptoms were not statistical outliers in our analysis. As only two studies measured eating-disorder-related symptoms as a primary outcome in our sample, these studies would have been excluded from diagnosis-specific meta-analysis. Therefore, we believe it was beneficial to use a transdiagnostic approach, despite the potential risk that our findings may differ between subcategories in the future. It is possible that some groups of symptoms may be particularly sensitive (or insensitive) to augmentative approaches, which will require a larger number of trials in each domain in the future.

One putative limitation is whether augmented psychological therapy involves additional overall contact time due to the duration of the augmentation, compared with standard interventions. For the majority of pharmacological and somatic augmentations, this was not the case: almost all used placebo medication (for example, refs. [32,49]), sham brain stimulation (for example, ref. [21]) or other somatic conditions (for example, refs. [24,50])—control groups with equivalent therapeutic contact time and duration. By contrast, several psychological augmentations involved additional contact time or duration, such as 15 minutes of hypnotic induction preceding cognitive behavioral therapy[51] (others, including cognitive bias modification[16], memory support[52] and imagery rescripting[53], explicitly equalized therapist contact time/duration between groups). However, evidence for psychological augmentations was the weakest of the three, suggesting that any increased contact time or duration was unlikely to drive the overall efficacy of augmentative approaches.

Given the debilitating effects of mental health disorders and the challenges in their treatment, improving mental health treatment is of the utmost economic and societal importance. For many decades, research has tended to conclude that psychological and pharmacological treatments are comparably efficacious, or that even different psychological therapies are equally effective (the 'dodo-bird verdict': that everybody has won and must have prizes[54]). This is despite differential treatment mechanisms within and between therapeutic modalities[55,56]. Improving on our current treatment paradigm may involve a paradigm shift towards individualized, mechanism-focused interventions. One approach to this is acute augmentations designed to optimize the specific subcomponents of therapy indicated for that particular patient. Augmentations of psychological therapy represent an area in which translational science can be directly tested, potentially improving clinical treatment rapidly and at scale. Future studies should investigate optimal combinations of augmentations and therapies, going beyond use of a single intervention to enhance a course of therapy and towards matching specific medications to the activities and contents of specific therapy sessions.

Additional augmentative domains could also be examined, for example augmentations focused on potentiating the therapeutic relationship or alliance[57]. Even our most effective psychiatric interventions leave many patients with clinically-significant problems. To move the needle on mental health interventions, we may need a different approach. Acute augmentations of psychological therapy represent a route from experimental science to clinical translation and may offer particular promise for precision psychiatry approaches. Our meta-analysis supports the usefulness of acute augmentations in the context of mostly smaller, experimental trials, but there remains a need for robust, real-world trials testing acute augmentation strategies.

Methods
Preregistration
Our meta-analysis was preregistered on PROSPERO (CRD42021236403). There were no deviations from the preregistered methods. We report both preregistered (primary) analyses and exploratory (secondary) analyses.

Inclusion criteria
We included studies in which the following were true.

- Participants had a diagnosed mental disorder[58] according to a validated questionnaire or interview assessment, or presented with subthreshold clinical symptoms, and in which the mean age of the sample was over 18 years. Mental disorders included mood disorders, anxiety disorders, eating disorders, personality disorders, psychotic disorders, trauma and stressor-related disorders, obsessive–compulsive disorder and substance-use disorders. Patients with comorbidities were not excluded.
- Treatment involved manualized psychological therapy (for example, cognitive behavioral therapy) combined with an acute augmentation (for example, exercise) administered before, during or after the therapy with the aim of enhancing the effect of the psychological therapy on mental health problems. Psychological therapy could have taken place face to face or online but was required to have been at least partially clinician led (not self-guided). Manualized therapies are those for which a manual or guide exists (for example, cognitive behavioral therapy for depression) and where the specific manual used is cited by the study authors.
- A control or comparison group for the acute augmentation was included, namely, a placebo drug, treatment as usual, another psychological treatment, wait list, sham brain stimulation or sham cognitive training. We recorded the primary mental health-related outcome reported in the study (for example, interview, self-report questionnaire or physiological measure). Included studies could be randomized or non-randomized controlled trials, including feasibility trials. Studies were required to include at least one session of psychological therapy and one acute augmentation aimed at enhancing the effects of the psychological therapy.

Exclusion criteria
We excluded studies aimed at treating neurological disorders or neuro-developmental disorders unless the primary outcome of the intervention was a mental health symptom. We also excluded studies in which the intervention was a longer-term combination treatment, the study did not report any mental health-related outcomes measured on a continuous scale, the study was a case report, case series, conference abstract or animal study or the data presented were insufficient to calculate effect sizes.

Information sources and search strategy
We conducted searches in the following databases: Medline (via Ovid), PsycINFO (via EBSCOhost) and Embase (via Ovid) (from inception until 2 February 2021; following a reviewer request to repeat searches, from inception until 25 May 2022). The full search terms used on each database are provided in Supplementary Information. We used a search strategy combining psychological therapy terms with augmentation-related terms, trial terms and psychiatric disorder-related terms using Boolean operators (>100 search terms included per database). Clinical trials registrations were also searched via ClinicalTrials.gov with the search terms (psychiatric disorder*) AND (behavioral OR pharmacological OR somatic) AND (psychological therapy).

We also performed reference tracing for additional studies meeting inclusion criteria referenced in the articles from our database searches.

To determine study suitability, we used a two-step approach. First, a minimum of two independent raters separately screened all titles and abstracts. Studies were excluded if they did not meet inclusion criteria on the basis of their title or abstract. Any discrepancies were resolved via discussion. Subsequently, the full text of the included studies was assessed by two independent raters to ensure these met inclusion criteria; discrepancies were again resolved by discussion.

The following information was collected from the included studies: author(s), year of publication, mental health assessment measure, mental health diagnosis or dimension studied, sample size, mean age, gender, types of interventions (augmentation(s) and control(s)), duration of interventions and outcome data (see the following).

Primary outcome data

We extracted summary data from reports by recording the primary mental health-related outcome reported in each study. If no measure was designated primary, or the primary outcome was categorical, we recorded the first continuous mental health-related outcome reported in the Results. If no continuous outcomes were reported, we excluded the study.

Grouping for synthesis

Our preregistered primary outcome was the standardized mean difference (Hedges' g) across all studies corresponding to the difference between the two groups at posttreatment (standardized mean difference) and the 95% confidence intervals around the effect sizes. We conducted random-effects meta-analysis due to anticipated between-study heterogeneity (confirmed in heterogeneity analyses (Results)).

We ran exploratory subgroup analyses using the same approach to obtain the effect size for each of three types of augmentations: (1) pharmacological (for example, cortisol or psilocybin), (2) psychological or cognitive (for example, attention bias modification or cognitive control training) and (3) somatic (nonpharmacological biological interventions, for example, transcranial magnetic stimulation or exercise).

Synthesis of results

In most studies, a lower value posttreatment indicated an improvement in mental health. In three studies, a higher value on their primary outcome indicated an improvement in symptoms, so mean values were multiplied by −1 to align the direction of the scales. Where we could not retrieve the relevant summary statistics from the text, the software WebPlotDigitizer was used to extract the data from figures where possible[59] (WebPlotDigitizer is accurate to the level of an individual pixel of the plot published; users can zoom in and out to select the most precise location within a pixel for data extraction. Intercoder reliability and validity of WebPlotDigitizer is high ($r = 0.999$ intercoder correlation)[60]. In studies that included multiple augmentation groups that all met criteria, the sample size, means and standard deviations for the multiple groups were combined, as per Cochrane recommendations[61]; we followed the same recommendation for studies reporting multiple active control groups (combining and treating as a single control group); for studies reporting active and inactive control groups, we always used the active control.

All analyses were performed in the statistical software environment R using the meta package[62]. We report pooled between-group effects by calculating Hedges' g corresponding to the difference between the augmentation group and the control group posttreatment (standardized mean difference)[63]. We also report the 95% confidence intervals around the effect sizes as a measure of certainty in the evidence for each pooled outcome. We used a random-effects model to calculate a pooled effect size and the Der Simonian–Laird method to estimate tau squared[64].

We used the I^2 statistic to assess the proportion of variability due to heterogeneity and calculated the Q statistic to test the existence of heterogeneity in our sample[30]. We interpreted the I^2 value according to the following guidelines: 25% representing low heterogeneity, 50% representing moderate heterogeneity and 75% representing high heterogeneity[30]. We also assessed the potential for publication bias via (1) visual inspection of a funnel plot and (2) Egger's regression test[65], and conducted a trim-and-fill analysis to assess the impact of including studies that may be missing due to publication bias[66].

Risk of bias

For each included study, we assessed risk of bias according to the Cochrane risk-of-bias tool[67]. This tool provides a framework for assessing different contributors to potential study bias originating from study design, conduct, analysis and reporting[67]. For each study, we assessed the use of random sequence generation, concealment of allocation, blinding of participants and treatment providers, blinding of outcome assessment and incomplete outcome data. We summarized each study's overall risk of bias following the Cochrane recommendation to use the domain(s) of most importance in the context of our meta-analysis[67]. We assessed blinding of outcome assessment to be the most critical risk in acute augmentations of psychotherapy trials. Therefore, we repeated our primary analysis excluding studies without blinded outcome assessment or with uncertain blinding of outcome assessment.

Reporting summary

Further information on research design is available in the Nature Portfolio Reporting Summary linked to this article.

Data availability

The preregistration can be found at https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42021236403, and all data can be found on the Open Science Framework: https://osf.io/a7x8j/.

Code availability

All relevant analysis code can also be found on the Open Science Framework: https://osf.io/a7x8j/.

References

1. *Depression and Other Common Mental Disorders* (WHO, 2017); http://apps.who.int/iris/bitstream/handle/10665/254610/WHOMSD?sequence=1
2. O'Shea, N. & Bell, A. *A Spending Review for Wellbeing* (Centre for Mental Health, 2020); https://www.centreformentalhealth.org.uk/sites/default/files/publication/download/CentreforMentalHealth_SpendingReviewForWellbeing.pdf
3. Ormel, J., Hollon, S. D., Kessler, R. C., Cuijpers, P. & Monroe, S. M. More treatment but no less depression: the treatment–prevalence paradox. *Clin. Psychol. Rev.* **91**, 102111 (2021).
4. Lazar, S. G. & Gabbard, G. O. The cost-effectiveness of psychotherapy. *J. Psychother. Pract. Res.* **6**, 307–314 (1997).
5. Zimmermann, G., Favrod, J., Trieu, V. & Pomini, V. The effect of cognitive behavioral treatment on the positive symptoms of schizophrenia spectrum disorders: a meta-analysis. *Schizophr. Res.* **77**, 1–9 (2005).
6. Linardon, J., Wade, T. D., De la Piedad Garcia, X. & Brennan, L. The efficacy of cognitive-behavioral therapy for eating disorders: a systematic review and meta-analysis. *J. Consult. Clin. Psychol.* **85**, 1080–1094 (2017).
7. Szentagotai, A. & David, D. The efficacy of cognitive-behavioral therapy in bipolar disorder: a quantitative meta-analysis. *J. Clin. Psychiatry* **71**, 66–72 (2010).
8. Cuijpers, P. et al. A network meta-analysis of the effects of psychotherapies, pharmacotherapies and their combination in the treatment of adult depression. *World Psychiatry* **19**, 92–107 (2020).
9. McEvoy, P. M., Erceg-Hurn, D. M., Barber, K. C., Dupasquier, J. R. & Moscovitch, D. A. Transportability of imagery-enhanced CBT for social anxiety disorder. *Behav. Res. Ther.* **106**, 86–94 (2018).
10. Davis, M., Ressler, K., Rothbaum, B. O. & Richardson, R. Effects of D-cycloserine on extinction: translation from preclinical to clinical work. *Biol. Psychiatry* **60**, 369–375 (2006).
11. Mataix-Cols, D. et al. D-cycloserine augmentation of exposure-based cognitive behavior therapy for anxiety, obsessive–compulsive,

and posttraumatic stress disorders: a systematic review and meta-analysis of individual participant data. *JAMA Psychiatry* **74**, 501–510 (2017).

12. Beck, A. T. in *Clinical Advances in Cognitive Psychotherapy: Theory and Application* (eds Leahy, R. L. and Dowd, E. T.) 29–61 (Springer, 2002).

13. Mackintosh, B., Mathews, A., Yiend, J., Ridgeway, V. & Cook, E. Induced biases in emotional interpretation influence stress vulnerability and endure despite changes in context. *Behav. Ther.* **37**, 209–222 (2006).

14. Lazarov, A. et al. Attention bias modification augments cognitive–behavioral group therapy for social anxiety disorder: a randomized controlled trial. *Psychol. Med.* **48**, 2177–2185 (2018).

15. Baker, A. et al. A pilot study augmenting cognitive behavioral therapy for panic disorder with attention bias modification: clinical and psychophysiological outcomes. *J. Behav. Ther. Exp. Psychiatry* **68**, 101568 (2020).

16. Falkenstein, M. J. et al. Feasibility and acceptability of cognitive bias modification for interpretation as an adjunctive treatment for OCD and related disorders: a pilot randomized controlled trial. *Behav. Ther.* **53**, 294–309 (2022).

17. Witkiewitz, K. et al. Mindfulness-based relapse prevention and transcranial direct current stimulation to reduce heavy drinking: a double-blind sham-controlled randomized trial. *Alcohol. Clin. Exp. Res.* **43**, 1296–1307 (2019).

18. Nord, C. L. et al. Neural predictors of treatment response to brain stimulation and psychological therapy in depression: a double-blind randomized controlled trial. *Neuropsychopharmacology* **44**, 1613–1622 (2019).

19. Cobb, A. R. et al. tDCS-augmented in vivo exposure therapy for specific fears: a randomized clinical trial. *J. Anxiety Disord.* **78**, 102344 (2021).

20. Nejati, V., Salehinejad, M. A., Shahidi, N. & Abedin, A. Psychological intervention combined with direct electrical brain stimulation (PIN-CODES) for treating major depression: a pre-test, post-test, follow-up pilot study. *Neurol. Psychiatry Brain Res.* **25**, 15–23 (2017).

21. Fryml, L. D. et al. Exposure therapy and simultaneous repetitive transcranial magnetic stimulation: a controlled pilot trial for the treatment of posttraumatic stress disorder. *J. ECT* **35**, 53–60 (2019).

22. Isserles, M. et al. Effectiveness of deep transcranial magnetic stimulation combined with a brief exposure procedure in post-traumatic stress disorder—a pilot study. *Brain Stimul.* **6**, 377–383 (2013).

23. Kozel, F. A. et al. Repetitive TMS to augment cognitive processing therapy in combat veterans of recent conflicts with PTSD: a randomized clinical trial. *J. Affect. Disord.* **229**, 506–514 (2018).

24. Bischoff, S. et al. Running for extinction? Aerobic exercise as an augmentation of exposure therapy in panic disorder with agoraphobia. *J. Psychiatric Res.* **101**, 34–41 (2018).

25. Chien, H., Chung, Y., Yeh, M. & Lee, J. Breathing exercise combined with cognitive behavioural intervention improves sleep quality and heart rate variability in major depression. *J. Clin. Nurs.* **24**, 3206–3214 (2015).

26. Shiban, Y. et al. Diaphragmatic breathing during virtual reality exposure therapy for aviophobia: functional coping strategy or avoidance behavior? A pilot study. *BMC Psychiatry* **17**, 29 (2017).

27. Dalgleish, T., Black, M., Johnston, D. & Bevan, A. Transdiagnostic approaches to mental health problems: current status and future directions. *J. Consult. Clin. Psychol.* **88**, 179–195 (2020).

28. Feinstein, A.R. & Cicchetti, D.V. High agreement but low kappa: I. The problems of two paradoxes. *J. Clin. Epidemiol.* **43**, 543–549 (1990).

29. Kotov, R. et al. The Hierarchical Taxonomy of Psychopathology (HiTOP): A dimensional alternative to traditional nosologies. *J. Abnorm. Psych.* **126**, 454 (2017).

30. Higgins, J. P. & Thompson, S. G. Quantifying heterogeneity in a meta-analysis. *Stat. Med.* **21**, 1539–1558 (2002).

31. Leichsenring, F., Steinert, C., Rabung, S. & Ioannidis, J. P. The efficacy of psychotherapies and pharmacotherapies for mental disorders in adults: an umbrella review and meta-analytic evaluation of recent meta-analyses. *World Psychiatry* **21**, 133–145 (2022).

32. Bouso, J. C., Doblin, R., Farré, M., Alcázar, M. Á. & Gómez-Jarabo, G. MDMA-assisted psychotherapy using low doses in a small sample of women with chronic posttraumatic stress disorder. *J. Psychoactive Drugs* **40**, 225–236 (2008).

33. Danforth, A. L. et al. Reduction in social anxiety after MDMA-assisted psychotherapy with autistic adults: a randomized, double-blind, placebo-controlled pilot study. *Psychopharmacology* **235**, 3137–3148 (2018).

34. Mithoefer, M. C., Wagner, M. T., Mithoefer, A. T., Jerome, L. & Doblin, R. The safety and efficacy of 3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study. *J. Psychopharmacol.* **25**, 439–452 (2011).

35. Mithoefer, M. C. et al. 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for post-traumatic stress disorder in military veterans, firefighters, and police officers: a randomised, double-blind, dose-response, phase 2 clinical trial. *Lancet Psychiatry* **5**, 486–497 (2018).

36. Nicholas, C. R. et al. The effects of MDMA-assisted therapy on alcohol and substance use in a phase 3 trial for treatment of severe PTSD. *Drug Alcohol Depend.* **233**, 109356 (2022).

37. Oehen, P., Traber, R., Widmer, V. & Schnyder, U. A randomized, controlled pilot study of MDMA (±3,4-methylenedioxymethamphetamine)-assisted psychotherapy for treatment of resistant, chronic post-traumatic stress disorder (PTSD). *J. Psychopharmacol.* **27**, 40–52 (2013).

38. Ot'alora G, M. et al. 3,4-Methylenedioxymethamphetamine-assisted psychotherapy for treatment of chronic posttraumatic stress disorder: a randomized phase 2 controlled trial. *J. Psychopharmacol.* **32**, 1295–1307 (2018).

39. Wolfson, P. E. et al. MDMA-assisted psychotherapy for treatment of anxiety and other psychological distress related to life-threatening illnesses: a randomized pilot study. *Sci. Rep.* **10**, 20442 (2020).

40. Davis, A. K. et al. Effects of psilocybin-assisted therapy on major depressive disorder: a randomized clinical trial. *JAMA Psychiatry* **78**, 481–489 (2021).

41. Ross, S. et al. Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. *J. Psychopharmacol.* **30**, 1165–1180 (2016).

42. Carhart-Harris, R. et al. Trial of psilocybin versus escitalopram for depression. *New Engl. J. Med.* **384**, 1402–1411 (2021).

43. Carhart-Harris, R. L. et al. Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. *Lancet Psychiatry* **3**, 619–627 (2016).

44. Mithoefer, M. C., Grob, C. S. & Brewerton, T. D. Novel psychopharmacological therapies for psychiatric disorders: psilocybin and MDMA. *Lancet Psychiatry* **3**, 481–488 (2016).

45. Wolpert, M., Pote, I. & Sebastian, C. L. Identifying and integrating active ingredients for mental health. *Lancet Psychiatry* **8**, 741–743 (2021).

46. Pile, V., Williamson, G., Saunders, A., Holmes, E. A. & Lau, J. Y. Harnessing emotional mental imagery to reduce anxiety and depression in young people: an integrative review of progress and promise. *Lancet Psychiatry* **8**, 836–852 (2021).

47. Nord, C. L., Dalmaijer, E. S., Armstrong, T., Baker, K. & Dalgleish, T. A causal role for gastric rhythm in human disgust avoidance. *Curr. Biol.* **31**, 629–634 (2021).

48. Sterne, J. A. et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. *Br. Med. J.* **343**, d4002 (2011).

49. Andersson, E. et al. D-cycloserine vs placebo as adjunct to cognitive behavioral therapy for obsessive–compulsive disorder and interaction with antidepressants: a randomized clinical trial. *JAMA Psychiatry* **72**, 659–667 (2015).

50. Lass-Hennemann, J. & Michael, T. Endogenous cortisol levels influence exposure therapy in spider phobia. *Behav. Res. Ther.* **60**, 39–45 (2014).

51. Alladin, A. & Alibhai, A. Cognitive hypnotherapy for depression: an empirical investigation. *Int. J. Clin. Exp. Hypn.* **55**, 147–166 (2007).

52. Harvey, A. G. et al. Improving outcome for mental disorders by enhancing memory for treatment. *Behav. Res. Ther.* **81**, 35–46 (2016).

53. Harb, G. C. et al. Randomized controlled trial of imagery rehearsal for posttraumatic nightmares in combat veterans. *J. Clin. Sleep Med.* **15**, 757–767 (2019).

54. Rosenzweig, S. Some implicit common factors in diverse methods of psychotherapy. *Am. J. Ophthalmol.* **6**, 412 (1936).

55. Nord, C. L. et al. Neural effects of antidepressant medication and psychological treatments: a quantitative synthesis across three metaanalyses. *Br J Psychiatry* **219**, 1–5 (2021).

56. Roiser, J. P., Elliott, R. & Sahakian, B. J. Cognitive mechanisms of treatment in depression. *Neuropsychopharmacology* **37**, 117–136 (2012).

57. Krupnick, J. L. et al. The role of the therapeutic alliance in psychotherapy and pharmacotherapy outcome: findings in the National Institute of Mental Health Treatment of Depression Collaborative Research Program. *Focus* **64**, 532–277 (2006).

58. American Psychiatric Association. Diagnostic and statistical manual of mental disorders (5th ed.). (American PsychiatricPublishing, 2013).

59. Rohatgi, A. WebPlotDigitizer (2021).

60. Drevon, D., Fursa, S. R. & Malcolm, A. L. Intercoder reliability and validity of WebPlotDigitizer in extracting graphed data. *Behav. Modif.* **41**, 323–339 (2017).

61. Cochrane handbook for systematic reviewsof interventions. Version 5.1. 0 [updated March 2011]. The Cochrane Collaboration. www.cochrane-handbook.org (2011).

62. Schwarzer, G., Carpenter, J. R. & Rücker, G. in *Meta-Analysis with R* 21–53 (Springer, 2015).

63. Hedges, L. V. & Olkin, I. *Statistical Methods for Meta-analysis* (Academic Press, 2014).

64. DerSimonian, R. & Laird, N. Meta-analysis in clinical trials. *Control. Clin. Trials* **7**, 177–188 (1986).

65. Egger, M., Smith, G. D., Schneider, M. & Minder, C. Bias in meta-analysis detected by a simple, graphical test. *Br. Med. J.* **315**, 629–634 (1997).

66. Duval, S. in *Publication Bias in Meta-Analysis: Prevention, Assessment and Adjustments* (eds Rothstein, H. R. et al.) 127–144 (Wiley, 2005).

67. Higgins, J. P. et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. *Br. Med. J.* **343**, d5928 (2011).

68. Brooks, H. et al. Enhancing cognition in older persons with depression or anxiety with a combination of mindfulness-based stress reduction (MBSR) and transcranial direct current stimulation (tDCS): results of a pilot randomized clinical trial. *Mindfulness* **12**, 3047–3059 (2021).

69. Arntz, A., Tiesema, M. & Kindt, M. Treatment of PTSD: a comparison of imaginal exposure with and without imagery rescripting. *J. Behav. Ther. Exp. Psychiatry* **38**, 345–370 (2007).

70. Aust, S. et al. Efficacy of augmentation of cognitive behavioral therapy with transcranial direct current stimulation for depression: a randomized clinical trial. *JAMA Psychiatry* **79**, 528–537 (2022).

71. Davis, M. C. et al. Oxytocin-augmented social cognitive skills training in schizophrenia. *Neuropsychopharmacology* **39**, 2070–2077 (2014).

72. Davis, M. L. et al. A randomized controlled study of power posing before public speaking exposure for social anxiety disorder: no evidence for augmentative effects. *J. Anxiety Disord.* **52**, 1–7 (2017).

73. Morissette, S. B., Spiegel, D. A. & Barlow, D. H. Combining exposure and pharmacotherapy in the treatment of social anxiety disorder: a preliminary study of state dependent learning. *J. Psychopathol. Behav. Assess.* **30**, 211–219 (2008).

74. Moshier, S. J. & Otto, M. W. Behavioral activation treatment for major depression: a randomized trial of the efficacy of augmentation with cognitive control training. *J. Affect. Disord.* **210**, 265–268 (2017).

75. Nations, K. R. et al. Evaluation of the glycine transporter inhibitor Org 25935 as augmentation to cognitive–behavioral therapy for panic disorder: a multicenter, randomized, double-blind, placebo-controlled trial. *J. Clin. Psychiatry* **73**, 647–653 (2012).

76. Otto, M. W. et al. Efficacy of d-cycloserine for enhancing response to cognitive–behavior therapy for panic disorder. *Biol. Psychiatry* **67**, 365–370 (2010).

77. Pace-Schott, E. F. et al. Effects of post-exposure naps on exposure therapy for social anxiety. *Psychiatry Res.* **270**, 523–530 (2018).

78. Powers, M. B., Smits, J. A., Otto, M. W., Sanders, C. & Emmelkamp, P. M. Facilitation of fear extinction in phobic participants with a novel cognitive enhancer: a randomized placebo controlled trial of yohimbine augmentation. *J. Anxiety Disord.* **23**, 350–356 (2009).

79. Pyrkosch, L. et al. Learn to forget: does post-exposure administration of d-cycloserine enhance fear extinction in agoraphobia? *J. Psychiatric Res.* **105**, 153–163 (2018).

80. Raeder, F. et al. Post-exposure cortisol administration does not augment the success of exposure therapy: a randomized placebo-controlled study. *Psychoneuroendocrinology* **99**, 174–182 (2019).

81. Reinecke, A., Nickless, A., Browning, M. & Harmer, C. J. Neurocognitive processes in d-cycloserine augmented single-session exposure therapy for anxiety: a randomized placebo-controlled trial. *Behav. Res. Ther.* **129**, 103607 (2020).

82. Reitmaier, J. et al. Effects of rhythmic eye movements during a virtual reality exposure paradigm for spider-phobic patients. *Psychol. Psychother.* **95**, 57–78 (2022).

83. Rodebaugh, T. L., Levinson, C. A. & Lenze, E. J. A high-throughput clinical assay for testing drug facilitation of exposure therapy. *Depress. Anxiety* **30**, 631–637 (2013).

84. Zoellner, L. A. et al. Enhancing extinction learning in posttraumatic stress disorder with brief daily imaginal exposure and methylene blue: a randomized controlled trial. *J. Clin. Psychiatry* **78**, e782–e789 (2017).

85. de Kleine, R. A., Hendriks, G.-J., Kusters, W. J., Broekman, T. G. & van Minnen, A. A randomized placebo-controlled trial of D-cycloserine to enhance exposure therapy for posttraumatic stress disorder. *Biol. Psychiatry* **71**, 962–968 (2012).

86. De Leeuw, A., van Megen, H., Kahn, R. & Westenberg, H. D-cycloserine addition to exposure sessions in the treatment of patients with obsessive–compulsive disorder. *Eur. Psychiatry* **40**, 38–44 (2017).

87. de Quervain, J.-F. et al. Glucocorticoids enhance extinction-based psychotherapy. *Proc. Natl Acad. Sci. USA* **108**, 6621–6625 (2011).

88. Difede, J. et al. D-cycloserine augmentation of exposure therapy for post-traumatic stress disorder: a pilot randomized clinical trial. *Neuropsychopharmacology* **39**, 1052–1058 (2014).

89. Diminich, E. D. et al. D-cycloserine augmentation of cognitive behavioral therapy for delusions: a randomized clinical trial. *Schizophr. Res.* **222**, 145–152 (2020).

90. Fayaz Feyzi, Y., Vahed, N., Sadeghamal Nikraftar, N. & Arezoomandan, R. Synergistic effect of combined transcranial direct current stimulation and Matrix Model on the reduction of methamphetamine craving and improvement of cognitive functioning: a randomized sham-controlled study. *Am. J. Drug Alcohol Abuse* **48**, 311–320 (2022).

91. Feng, B. et al. Transcutaneous electrical acupoint stimulation for post-traumatic stress disorder: assessor-blinded, randomized controlled study. *Psychiatry Clin. Neurosci.* **73**, 179–186 (2019).

92. Flanagan, J. C., Sippel, L. M., Wahlquist, A., Moran-Santa Maria, M. M. & Back, S. E. Augmenting prolonged exposure therapy for PTSD with intranasal oxytocin: a randomized, placebo-controlled pilot trial. *J. Psychiatric Res.* **98**, 64–69 (2018).

93. Foa, E. B. et al. Randomized trial of prolonged exposure for posttraumatic stress disorder with and without cognitive restructuring: outcome at academic and community clinics. *J. Consult. Clin. Psychol.* **73**, 953 (2005).

94. Guastella, A. J. et al. A randomized controlled trial of D-cycloserine enhancement of exposure therapy for social anxiety disorder. *Biol. Psychiatry* **63**, 544–549 (2008).

95. Guastella, A. J., Howard, A. L., Dadds, M. R., Mitchell, P. & Carson, D. S. A randomized controlled trial of intranasal oxytocin as an adjunct to exposure therapy for social anxiety disorder. *Psychoneuroendocrinology* **34**, 917–923 (2009).

96. Hofmann, S. G. et al. Augmentation of exposure therapy with D-cycloserine for social anxiety disorder. *Arch. Gen. Psychiatry* **63**, 298–304 (2006).

97. Hofmann, S. G. et al. D-cycloserine as an augmentation strategy with cognitive–behavioral therapy for social anxiety disorder. *Am. J. Psychiatry* **170**, 751–758 (2013).

98. Hofmeijer-Sevink, M. K. et al. No effects of D-cycloserine enhancement in exposure with response prevention therapy in panic disorder with agoraphobia: a double-blind, randomized controlled trial. *J. Clin. Psychopharmacol.* **37**, 531–539 (2017).

99. Hutschemaekers, M. H. M., de Kleine, R. A., Hendriks, G.-J., Kampman, M. & Roelofs, K. The enhancing effects of testosterone in exposure treatment for social anxiety disorder: a randomized proof-of-concept trial. *Transl. Psychiatry* **11**, 432 (2021).

100. Isserles, M. et al. Deep transcranial magnetic stimulation combined with brief exposure for posttraumatic stress disorder: a prospective multisite randomized trial. *Biol. Psychiatry* **90**, 721–728 (2021).

101. Janse, P. D. et al. The effect of feedback-informed cognitive behavioral therapy on treatment outcome: a randomized controlled trial. *J. Consult. Clin. Psychol.* **88**, 818–828 (2020).

102. Kamboj, S. K. et al. Cue exposure and response prevention with heavy smokers: a laboratory-based randomised placebo-controlled trial examining the effects of D-cycloserine on cue reactivity and attentional bias. *Psychopharmacology* **221**, 273–284 (2012).

103. Krupitsky, E. et al. Ketamine psychotherapy for heroin addiction: immediate effects and two-year follow-up. *J. Subst. Abuse Treat.* **23**, 273–283 (2002).

104. Kushner, M. G. et al. D-cycloserine augmented exposure therapy for obsessive–compulsive disorder. *Biol. Psychiatry* **62**, 835–838 (2007).

105. Kwee, C. M. et al. Cannabidiol enhancement of exposure therapy in treatment refractory patients with social anxiety disorder and panic disorder with agoraphobia: a randomised controlled trial. *Eur. Neuropsychopharmacol.* **59**, 58–67 (2022).

106. Lancaster, C. L., Monfils, M.-H. & Telch, M. J. Augmenting exposure therapy with pre-extinction fear memory reactivation and deepened extinction: a randomized controlled trial. *Behav. Res. Ther.* **135**, 103730 (2020).

107. Lee, J. Y., Dong, L., Gumport, N. B. & Harvey, A. G. Establishing the dose of memory support to improve patient memory for treatment and treatment outcome. *J. Behav. Ther. Exp. Psychiatry* **68**, 101526 (2020).

108. Lehrner, A. et al. A randomized, double-blind, placebo-controlled trial of hydrocortisone augmentation of prolonged exposure for PTSD in US combat veterans. *Behav. Res. Ther.* **144**, 103924 (2021).

109. Leuchter, M. K. et al. Treatment of spider phobia using repeated exposures and adjunctive repetitive transcranial magnetic stimulation: a proof-of-concept study. *Front. Psychiatry* **13**, 823158 (2022).

110. Litz, B. T. et al. A randomized placebo-controlled trial of D-cycloserine and exposure therapy for posttraumatic stress disorder. *J. Psychiatric Res.* **46**, 1184–1190 (2012).

111. Maples-Keller, J. L. et al. Targeting memory reconsolidation to prevent the return of fear in patients with fear of flying. *Depress. Anxiety* **34**, 610–620 (2017).

112. Marker, I., Corbett, B. E., Drummond, S. P. A. & Norton, P. J. Intermittent motivational interviewing and transdiagnostic CBT for anxiety: a randomized controlled trial. *J. Anxiety Disord.* **75**, 102276 (2020).

113. Meyer, E. et al. A randomized clinical trial to examine enhancing cognitive–behavioral group therapy for obsessive–compulsive disorder with motivational interviewing and thought mapping. *Behav. Cogn. Psychother.* **38**, 319–336 (2010).

114. Meyer, J. D. et al. Feasibility of an exercise and CBT intervention for treatment of depression: a pilot randomized controlled trial. *Front. Psychiatry* **13**, 799600 (2022).

115. Meyerbroeker, K., Powers, M. B., Van Stegeren, A. & Emmelkamp, P. M. Does yohimbine hydrochloride facilitate fear extinction in virtual reality treatment of fear of flying? A randomized placebo-controlled trial. *Psychother. Psychosom.* **81**, 29–37 (2012).

116. Meyerbröker, K., Morina, N. & Emmelkamp, P. Enhancement of exposure therapy in participants with specific phobia: a randomized controlled trial comparing yohimbine, propranolol and placebo. *J. Anxiety Disord.* **57**, 48–56 (2018).

117. Ross, S. et al. Acute and sustained reductions in loss of meaning and suicidal ideation following psilocybin-assisted psychotherapy for psychiatric and existential distress in life-threatening cancer. *ACS Pharmacol. Transl. Sci.* **4**, 553–562 (2021).

118. Rubin, M., Muller, K., Hayhoe, M. M. & Telch, M. J. Attention guidance augmentation of virtual reality exposure therapy for social anxiety disorder: a pilot randomized controlled trial. *Cogn. Behav. Ther.* **0**, 1–17 (2022).

119. Santa Ana, E. J. et al. D-cycloserine combined with cue exposure therapy fails to attenuate subjective and physiological craving in cocaine dependence. *Am. J. Addict.* **24**, 217–224 (2015).

120. Sherman, B. J., Baker, N. L. & McRae-Clark, A. L. Effect of oxytocin pretreatment on cannabis outcomes in a brief motivational intervention. *Psychiatry Res.* **249**, 318–320 (2017).

121. Siegmund, A. et al. D-cycloserine does not improve but might slightly speed up the outcome of in-vivo exposure therapy in patients with severe agoraphobia and panic disorder in a randomized double blind clinical trial. *J. Psychiatric Res.* **45**, 1042–1047 (2011).

122. Simpson, H. B. et al. Challenges using motivational interviewing as an adjunct to exposure therapy for obsessive–compulsive disorder. *Behav. Res.Ther.* **48**, 941–948 (2010).

123. Sippel, L. M., King, C. E., Wahlquist, A. E. & Flanagan, J. C. A preliminary examination of endogenous peripheral oxytocin in a pilot randomized clinical trial of oxytocin-enhanced psychotherapy for posttraumatic stress disorder. *J. Clin. Psychopharmacol.* **40**, 401–404 (2020).

124. Smits, J. A., Powers, M. B., Buxkamper, R. & Telch, M. J. The efficacy of videotape feedback for enhancing the effects of exposure-based treatment for social anxiety disorder: a controlled investigation. *Behav. Res. Ther.* **44**, 1773–1785 (2006).

125. Smits, J. A. et al. Yohimbine enhancement of exposure therapy for social anxiety disorder: a randomized controlled trial. *Biol. Psychiatry* **75**, 840–846 (2014).

126. Smits, J. A. J. et al. Dose timing of D-cycloserine to augment exposure therapy for social anxiety disorder: a randomized clinical trial. *JAMA Netw. Open* **3**, e206777 (2020).

127. Smits, J. A. J. et al. Enhancing panic and smoking reduction treatment with D-cycloserine: a pilot randomized clinical trial. *Drug Alcohol Depend.* **208**, 107877 (2020).

128. Soravia, L. M. et al. Glucocorticoids enhance in vivo exposure-based therapy of spider phobia. *Depress. Anxiety* **31**, 429–435 (2014).

129. Soucy, J. N., Hadjistavropoulos, H. D., Karin, E., Dear, B. F. & Titov, N. Brief online motivational interviewing pre-treatment intervention for enhancing internet-delivered cognitive behaviour therapy: a randomized controlled trial. *Internet Interv.* **25**, 100394 (2021).

130. Steudte-Schmiedgen, S., Fay, E., Capitao, L., Kirschbaum, C. & Reinecke, A. Hydrocortisone as an adjunct to brief cognitive–behavioural therapy for specific fear: endocrine and cognitive biomarkers as predictors of symptom improvement. *J. Psychopharmacol.* **35**, 641–651 (2021).

131. Storch, E. A. et al. D-cycloserine does not enhance exposure–response prevention therapy in obsessive–compulsive disorder. *Int. Clin. Psychopharmacol.* **22**, 230–237 (2007).

132. Tart, C. D. et al. Augmentation of exposure therapy with post-session administration of D-cycloserine. *J. Psychiatric Res.* **47**, 168–174 (2013).

133. Tuerk, P. W. et al. Augmenting treatment efficiency in exposure therapy for PTSD: a randomized double-blind placebo-controlled trial of yohimbine HCl. *Cogn. Behav. Ther.* **47**, 351–371 (2018).

134. Vermes, J. S. et al. Targeting the reconsolidation of traumatic memories with a brief 2-session imaginal exposure intervention in post-traumatic stress disorder. *J. Affect. Disord.* **276**, 487–494 (2020).

135. Weingarden, H. et al. D-cycloserine-augmented behavior therapy for body dysmorphic disorder: a preliminary efficacy trial. *Cogn. Ther. Res.* **43**, 937–947 (2019).

136. Wilhelm, S. et al. Augmentation of behavior therapy with D-cycloserine for obsessive–compulsive disorder. *Am. J. Psychiatry* **165**, 335–341 (2008).

137. McEvoy, P. M. et al. Imagery-enhanced v. verbally-based group cognitive behavior therapy for social anxiety disorder: a randomized clinical trial. *Psychol. Med.* **52**, 1277–1286 (2020).

138. Acheson, D. T., Feifel, D., Kamenski, M., Mckinney, R. & Risbrough, V. B. Intranasal oxytocin administration prior to exposure therapy for arachnophobia impedes treatment response. *Depress. Anxiety* **32**, 400–407 (2015).

139. Bryant, R. A., Moulds, M. L., Guthrie, R. M. & Nixon, R. D. The additive benefit of hypnosis and cognitive–behavioral therapy in treating acute stress disorder. *J. Consult. Clin. Psychol.* **73**, 334–340 (2005).

140. Bryant, R. A. et al. A randomized controlled trial of exposure therapy and cognitive restructuring for posttraumatic stress disorder. *J. Consult. Clin. Psychol.* **76**, 695 (2008).

141. Buchanan, R. W. et al. Combined oxytocin and cognitive behavioral social skills training for social function in people with schizophrenia. *J. Clin. Psychopharmacol.* **41**, 236–243 (2021).

142. Burton, L. E., Qeadan, F. & Burge, M. R. Efficacy of equine-assisted psychotherapy in veterans with posttraumatic stress disorder. *J. Integrat. Med.* **17**, 14–19 (2019).

143. Cesa, G. L. et al. Virtual reality for enhancing the cognitive behavioral treatment of obesity with binge eating disorder: randomized controlled study with one-year follow-up. *J. Med. Internet Res.* **15**, e2441 (2013).

144. Coffey, S. F. et al. Trauma-focused exposure therapy for chronic posttraumatic stress disorder in alcohol and drug dependent patients: a randomized controlled trial. *Psychol. Addict. Behav.* **30**, 778 (2016).

145. Contalbrigo, L. et al. The efficacy of dog assisted therapy in detained drug users: a pilot study in an Italian attenuated custody institute. *Int. J. Environ. Res. Public Health* **14**, 683 (2017).

146. Craske, M. G., Fanselow, M., Treanor, M. & Bystritksy, A. Cholinergic modulation of exposure disrupts hippocampal processes and augments extinction: proof-of-concept study with social anxiety disorder. *Biol. Psychiatry* **86**, 703–711 (2019).

147. Thierrée, S. et al. Combining trauma script exposure with rTMS to reduce symptoms of post-traumatic stress disorder: randomized controlled trial. *Neuromodulation* **25**, 549–557 (2022).

Author contributions

The study was conceived by C.L.N. and T.D. All authors had full access to all the data in the study and had final responsibility for the decision to submit for publication. All data were independently accessed by C.L.N. and B.L. (first screening) and by C.L.N. and J.F. (second screening), and subsets of the data were accessed by A.J.S., Q.D., S.G. and R.K. Initial searches were conducted by C.L.N. and B.L.; final searches were conducted by V.P. and B.L. B.L., C.L.N., A.J.S., Q.D., S.G., J.F. and R.K. screened titles and abstracts. C.L.N. and B.L. (first round) and J.F. (second round) screened full texts. B.L. and C.L.N. conducted initial analyses. Q.D. conducted all final analyses and made figures. C.L.N. and B.L. wrote the paper, which was edited by Q.D., A.J.S., S.G., R.K., V.P. and T.D. Funding was acquired by T.D. and C.L.N.; supervision and oversight were provided by T.D. and C.L.N.

Competing interests

The authors declare no competing interests.

Additional information

Supplementary information The online version contains supplementary material available at https://doi.org/10.1038/s44220-023-00048-6.

Correspondence and requests for materials should be addressed to Camilla L. Nord.

Peer review information *Nature Mental Health* thanks David Berle, Robert McCutcheon and the other, anonymous, reviewer(s) for their contribution to the peer review of this work.

Reprints and permissions information is available at www.nature.com/reprints.

nature portfolio

Corresponding author(s): Nord

Last updated by author(s): Feb 17, 2023

Reporting Summary

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our Editorial Policies and the Editorial Policy Checklist.

Statistics

For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.

n/a	Confirmed	
☐	☒	The exact sample size (*n*) for each experimental group/condition, given as a discrete number and unit of measurement
☐	☒	A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
☐	☒	The statistical test(s) used AND whether they are one- or two-sided *Only common tests should be described solely by name; describe more complex techniques in the Methods section.*
☐	☒	A description of all covariates tested
☐	☒	A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
☐	☒	A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
☐	☒	For null hypothesis testing, the test statistic (e.g. *F*, *t*, *r*) with confidence intervals, effect sizes, degrees of freedom and *P* value noted *Give P values as exact values whenever suitable.*
☒	☐	For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
☒	☐	For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
☐	☒	Estimates of effect sizes (e.g. Cohen's *d*, Pearson's *r*), indicating how they were calculated

Our web collection on statistics for biologists contains articles on many of the points above.

Software and code

Policy information about availability of computer code

Data collection	Data collection was collected by manually recording outcomes reported in studies. For a small minority, this included extraction of results using WebPlotDigitizer v4.6.
Data analysis	Analyses were performed in R version 4.0.3 (2020-10-10) using the meta package.

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio guidelines for submitting code & software for further information.

Data

Policy information about availability of data

All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:
- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our policy

All data can be found on the Open Science Framework: https://osf.io/a7x8j/

Human research participants

Policy information about [studies involving human research participants and Sex and Gender in Research.](#)

Reporting on sex and gender	This information was not collected (meta-analysis of existing data; not relevant to pre-registered question)
Population characteristics	This information is described in Supplemental Table S2 due to the number of studies included.
Recruitment	N/A meta-analysis
Ethics oversight	N/A - meta-analysis

Note that full information on the approval of the study protocol must also be provided in the manuscript.

Field-specific reporting

Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

☐ Life sciences ☐ Behavioural & social sciences ☐ Ecological, evolutionary & environmental sciences

For a reference copy of the document with all sections, see [nature.com/documents/nr-reporting-summary-flat.pdf](#)

Life sciences study design

All studies must disclose on these points even when the disclosure is negative.

Sample size	*Describe how sample size was determined, detailing any statistical methods used to predetermine sample size OR if no sample-size calculation was performed, describe how sample sizes were chosen and provide a rationale for why these sample sizes are sufficient.*
Data exclusions	*Describe any data exclusions. If no data were excluded from the analyses, state so OR if data were excluded, describe the exclusions and the rationale behind them, indicating whether exclusion criteria were pre-established.*
Replication	*Describe the measures taken to verify the reproducibility of the experimental findings. If all attempts at replication were successful, confirm this OR if there are any findings that were not replicated or cannot be reproduced, note this and describe why.*
Randomization	*Describe how samples/organisms/participants were allocated into experimental groups. If allocation was not random, describe how covariates were controlled OR if this is not relevant to your study, explain why.*
Blinding	*Describe whether the investigators were blinded to group allocation during data collection and/or analysis. If blinding was not possible, describe why OR explain why blinding was not relevant to your study.*

Behavioural & social sciences study design

All studies must disclose on these points even when the disclosure is negative.

Study description	This is a quantitative study: a meta-analysis.
Research sample	This study is comprised of 108 samples (existing studies), which were sourced from the literature (see Supplementary Methods 1.1). The rationale for this was to combine the effect sizes using meta-analytic techniques to describe a summary effect size, across all studies and across specific study sub-categories. For each study/sample, the number, mean age of each group, gender (as % female), and intervention can be found in Supplemental Table 2. The original data do not describe whether or not the sample is representative of the specific patient populations investigated.
Sampling strategy	This is not relevant to a meta-analysis, which involves finding (or attempting to find) every study in the literature that meets our pre-registered inclusion criteria. The number of datasets in the study are determined on the basis of every accessible study we can find that meet our inclusion criteria. This does not meet the descriptors of random, snowball, stratified, or convenience sampling.
Data collection	A minimum of two independent reviewers screened all studies for inclusion. Data were recorded on laptops and desktop computers in Microsoft Excel by conducting searches in Medline (via Ovid), PsycINFO (via EBSCOhost), and Embase (via Ovid) (from inception up until 2nd February 2021; following a reviewer request to repeat searches, from inception up until May 25th 2022). Researchers could not be blinded to conditions or hypothesis given the nature of this study (a meta-analysis).
Timing	Data was collected on 2nd February 2021; and following reviewer suggestion on May 25th 2022

Data exclusions	Exclusion criteria were pre-established. We excluded 20,868 studies that did not meet our pre-registered inclusion criteria.
Non-participation	*State how many participants dropped out/declined participation and the reason(s) given OR provide response rate OR state that no participants dropped out/declined participation.*
Randomization	This study was a meta-analysis. Randomization of each individual of the 108 studies is described in the manuscript: 106 studies were randomised, and two were non-randomised; the data was analysed with and without these studies (see "Sensitivity analyses"), but the meta-analysis itself cannot be randomised in this sense.

Ecological, evolutionary & environmental sciences study design

All studies must disclose on these points even when the disclosure is negative.

Study description	*Briefly describe the study. For quantitative data include treatment factors and interactions, design structure (e.g. factorial, nested, hierarchical), nature and number of experimental units and replicates.*
Research sample	*Describe the research sample (e.g. a group of tagged Passer domesticus, all Stenocereus thurberi within Organ Pipe Cactus National Monument), and provide a rationale for the sample choice. When relevant, describe the organism taxa, source, sex, age range and any manipulations. State what population the sample is meant to represent when applicable. For studies involving existing datasets, describe the data and its source.*
Sampling strategy	*Note the sampling procedure. Describe the statistical methods that were used to predetermine sample size OR if no sample-size calculation was performed, describe how sample sizes were chosen and provide a rationale for why these sample sizes are sufficient.*
Data collection	*Describe the data collection procedure, including who recorded the data and how.*
Timing and spatial scale	*Indicate the start and stop dates of data collection, noting the frequency and periodicity of sampling and providing a rationale for these choices. If there is a gap between collection periods, state the dates for each sample cohort. Specify the spatial scale from which the data are taken*
Data exclusions	*If no data were excluded from the analyses, state so OR if data were excluded, describe the exclusions and the rationale behind them, indicating whether exclusion criteria were pre-established.*
Reproducibility	*Describe the measures taken to verify the reproducibility of experimental findings. For each experiment, note whether any attempts to repeat the experiment failed OR state that all attempts to repeat the experiment were successful.*
Randomization	*Describe how samples/organisms/participants were allocated into groups. If allocation was not random, describe how covariates were controlled. If this is not relevant to your study, explain why.*
Blinding	*Describe the extent of blinding used during data acquisition and analysis. If blinding was not possible, describe why OR explain why blinding was not relevant to your study.*

Did the study involve field work? ☐ Yes ☐ No

Field work, collection and transport

Field conditions	*Describe the study conditions for field work, providing relevant parameters (e.g. temperature, rainfall).*
Location	*State the location of the sampling or experiment, providing relevant parameters (e.g. latitude and longitude, elevation, water depth).*
Access & import/export	*Describe the efforts you have made to access habitats and to collect and import/export your samples in a responsible manner and in compliance with local, national and international laws, noting any permits that were obtained (give the name of the issuing authority, the date of issue, and any identifying information).*
Disturbance	*Describe any disturbance caused by the study and how it was minimized.*

Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

Materials & experimental systems

n/a	Involved in the study
☒	☐ Antibodies
☒	☐ Eukaryotic cell lines
☒	☐ Palaeontology and archaeology
☒	☐ Animals and other organisms
☒	☐ Clinical data
☒	☐ Dual use research of concern

Methods

n/a	Involved in the study
☒	☐ ChIP-seq
☒	☐ Flow cytometry
☒	☐ MRI-based neuroimaging